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ABBREVIATIONS

CAPS - Competitive Armenian Private Sector
DRA - Drug regulatory authority
DURG – Drug Utilization Research Group
EML - Essential medicines list
EU – European Union
FDA – Food and Drug Administration (in the United States)
GLP - Good laboratory practice
GMP - Good manufacturing practice
GPP - Good pharmacy practice
MoH – Ministry of Health
NMP – National medicines policy
NA – National Assembly
PPP – pharmaceutical policy process
RA – Republic of Armenia
SCDMTE - Scientific Centre of Drug and Medical Technology Expertise (in Armenia)
STG – Standard treatment guidelines
VAT – Value-added tax
WHO – World Health Organization
WFP - World Food Programme
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EXECUTIVE SUMMARY
Although the pharmaceutical sector in Armenia is currently mainly established, some
challenges still cause a big concern. Such facts as a lack of important policies on
pharmaceuticals, an outdated legislation and a lack of regulation suggest that the
pharmaceutical policy process in Armenia is not effective enough and its insufficient
effectiveness is one of the most important barriers for successful implementation of
pharmaceutical reforms in the country. The goal of this capstone was to analyze
pharmaceutical policy process in Armenia and other Newly Independent States and to
develop recommendations for Armenia. Data and information were obtained from
publication searches and unpublished sources; two interviews with key informants were
conducted – one from Armenia and one from Russia.
It was defined that the main challenges in in the Armenian pharmaceutical sector are a
lack of access to medicines, appearing of counterfeit products and irrational use. The results
of assessment of the current pharmaceutical policy framework in Armenia have shown that
17 of 44 policies recommended by the World Health Organization (WHO) are approved and
additional 11 are implemented although are not formally approved. The results of the
assessment also shown that the number of policies introduced in the different components
varies: the best ratio of approved to recommended policies is observed in the area of
Regulation and Quality Assurance while the no policies have been developed on
Monitoring; only a few policies are available in the fields of Affordability and Rational Use.
Assessment of effectiveness of Pharmaceutical policy process (PPP) in Armenia conducted
according to process and outcome indicators developed has shown that PPP in Armenia is
not sufficiently effective because process often do not reach its outcomes – well developed
4

and actively discussed drafts of policy documents are not approved without any clear
reason, plans for implementation of those that were approved are conducted only partly and
evaluation is never done. Strengths and weaknesses of PPP in Armenia were defined based
on analyzing the situation in the country.
Based on studying experience of Newly Independent States (NIS) on PPP some
lessons that can be used by policy-makers in Armenia were formulated: having formally
approved document of NMP can be considered to be useful for improving the situation in
the pharmaceutical sector; it is preferable to approve a NMP document at the governmental
or higher level; it is important to make a draft of NMP document publicly available and
provide conditions for wide consideration with involving different stakeholders; it is also
important not only collect suggestions, but also to take them into account; due to absence of
system of monitoring and evaluation countries are not able to evaluate their progress in the
pharmaceutical sector even if they fix changes of some indicators; patients’ including
consumers’ organizations are currently not able to make a difference in the pharmaceutical
policy process in NIS. Framework of pharmaceutical policy process involving advocacy
coalition was developed.
Recommendations for different stakeholders were developed. For the Government:
to create a Multi-sectoral Commission responsible for pharmaceutical policy issues; to
ensure that the Commission consists of representatives of different stakeholders including
organizations representing patients’ rights; to ensure an access of media to meetings; to
ensure transparency of the commission’s activity; to create and introduce mechanisms for
enforcement of existing legislation in the pharmaceutical sector. For the Ministry of Health:
to implement comprehensive assessment of the pharmaceutical sector; to create a working
5

group consisting of leading national experts and representatives of different stakeholders to
develop a draft of a National Medicines Policy document; to develop a draft of the five-year
Implementation plan together with NMP and present it together with a policy document
draft; to consider drafts with all the interested stakeholders during initially decided period of
time, make changes based on presented comments and approve it as a Government
Resolution; to create in MoH a special unit responsible for monitoring and evaluation of
NMP; to create a Public Commission (involving representatives of patients’, consumers’
and other non-governmental organizations) to be involved in considerations of the results of
policy monitoring and evaluation; to provide transparency of unit’s activity and results
received; to monitor PPP according to indicators suggested and to provide the results to
above- mentioned Public Commission for consideration and revision; to calculate, identify
and ensure funding needed for policy implementation. For Public (Non-Governmental)
organizations - both professional associations and representing patients’ interests: to
participate actively in pharmaceutical policy formulation and consideration; to be informed
about the results of monitoring and evaluation and possible changes in policy; to create a
strong advocacy coalition involving professional associations and consumer’s rights
organizations, media and so forth, that would be able to defend interests of patients. For
International Non-Governmental) organizations: to provide some funding to ensure active
participation of NGOs in policy process and their independence.
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INTRODUCTION
Armenia is one of twelve (of the total fifteen) former Republics of the Soviet Union
which were and are still referred to as the Newly Independent States (NIS). In 1991,
Armenia formally declared its independence and started the transition process from socialist
to market-oriented economy. In its attempts to reach quick achievements Armenia selected a
strategy of rapid reforms in economic and other sectors. Similar to other NIS, Armenia has
faced numerous political, economic and social challenges. “Transition has had a serious and
long-term impact on the income and well-being of the population.” (Hakobyan, 2006, p.xv).
Today the socioeconomic situation in the country is much improved, including the area
of health care. However, many challenges still exist because implementation of unique
comprehensive reforms (cardinally changing the legislation, an organization structure,
supply system, financing, pricing and payment systems, etc.) under the conditions of
additional difficulties of the transitional period (such as the collapse of the former supply
systems, lack of funding, lack of experience, some wrong assumptions, psychological
transformation, etc.) was an extremely difficult task and the twenty years period of time was
not sufficient to overcome completely problems appeared due to transition to another
economic system and the collapse of the country (the former USSR). For example, although
the pharmaceutical sector in Armenia is currently mainly established, a lack of access to
medicines, appearing of counterfeit products and irrational use still cause a big concern.
At the same time it seems that although objective difficulties (lack of funding, lack of
resources, etc.) including those caused by the transition time have been and continue to be a
significant barrier for improvement of the situation, outcomes in the pharmaceutical sector
could be better if the Government and other main stakeholders would make more efforts in
7

this field and if these efforts would be better managed. Recently the President of Armenia S.
Sargsyan has criticized the situation in the health care including issues related to
pharmaceuticals as well as inaction of officials in the Ministry of Health and other
organizations (Regnum, 2012). This clearly indicated a lack of efforts at the Governmental
level that can be a serious constraint for successful pharmaceutical policy. Furthermore,
such facts as a lack of important policies on pharmaceuticals, an outdated legislation and a
lack of regulation suggest that the pharmaceutical policy process in Armenia is not effective
enough and its insufficient effectiveness is one of the most important barriers for successful
implementation of pharmaceutical reforms in the country.
There are currently some political signs in Armenia (attention from the President to
problems related to medicines and his promises about improvements in this field expressed
during election campaign; increased support on the part of the Public to representatives of
policy opposition that forces the Government to pay more attention to social problems
including health care) and opportunities (relatively new Minister of Health who is interested
in improving performance in the pharmaceutical sector and is able to provide necessary
political will, recently approved Governmental decision on the program addressing
problems in the pharmaceutical policy) which are able to bring issues related to medicines to
policy agenda and create conditions for reform implementation. Nevertheless, it is hard to
expect that a comprehensive pharmaceutical reform will be implemented successfully until
the pharmaceutical policy process in Armenia is changed.

8

Background
National pharmaceutical policy as a framework to address challenges in the
pharmaceutical sector
According to the World Health Organization (WHO) recommendations, a national
medicines policy (NMP) provides a common framework within which various problems
related to pharmaceuticals, especially those which are complicated and interdependent, can
be addressed (WHO, 2001). NMP presents the medium- to long-term goals and strategies
aimed at achieving them for the pharmaceutical sector which are set by the government; it
“is a commitment to a goal and a guide for action” (WHO, 2003, p.1). When suggesting
having a comprehensive pharmaceutical policy, WHO recommends countries have a
formally approved NMP document covering the following components: selection of
essential medicines, affordability, financing options, supply systems, regulation and quality
assurance, rational use, research, human resources, monitoring and evaluation (WHO, 2001;
WHO, 2003). “WHO recommends that all countries formulate and implement a
comprehensive national drug policy (NDP)” (WHO, 2001, p.4). According to the WHO
data, in 2007 62 (of 118 covered) countries had an official NMP (WHO, 2009). Currently
mainly low- and middle- income countries develop such a comprehensive policy. Australia
was one of the first developed countries that approved an official comprehensive NMP in
2000 (WHO, 2003). In 2011 “Medicines policy 2020” was approved in Finland (MSAH,
2011). Comprehensive NMP seems to be especially important for countries carrying out
large-scale reforms, and all the Newly Independent States are such countries.
The approaches to a nation’s pharmaceutical policy used by Roberts & Reich (2011) and
Seiter (2010) are slightly different from those of WHO; in particular, when considering
9

pharmaceutical policy these authors do not focus on a comprehensive National policy
document. Roberts & Reich (2011) mean by pharmaceutical policy “conscious efforts of
national governments to influence the functioning of these subsystems”; these subsystems
are the following: R&D, clinical trials, registration, manufacturing and packaging,
procurement and importing, supply chain, dispensing and sales, use (p. 5). Seiter (2010)
defined policy as “conscious attempt of public officials or executives entrusted with public
funds to achieve certain objectives through a set of laws, rules, procedures, and incentives”
(p.1).
For this Capstone I define the pharmaceutical policy as the results of conscious attempts
of national legislators, the Government and other public officials to influence the
functioning of the pharmaceutical sector through a set of or separate law(s), regulation
document(s), orders and/or actions including approval and implementation a comprehensive
National medicines policy document.
Based on key attributes of public policy suggested by Birkland (2010), I would suggest
the following attributes of the pharmaceutical policy:
 Pharmaceutical policy is made by public official even if ideas/suggestions/drafts
of documents come from outside or are developed through collective efforts with
other stakeholders.
 Pharmaceutical policy is intended to be implemented not only by public officials,
but also by different public and private institutions having their own interests.
 Pharmaceutical policy is mainly made in response to the problem(s) related to
medicines.
 Pharmaceutical policy is both - what the government choses to do and not to do.
10

Approaches to Pharmaceutical Policy Process
According to Birkland (2011), the term “policy process” suggests existence of a system
“that translates policy ideas into actual policies that are implemented and have positive
effect” (p.25). My experience with evaluating the pharmaceutical policy process suggests
that policy ideas are not always are implemented even if policy is approved, and the effect
of policies is not always positive even if positive outcomes have been planned. Roberts &
Reich (2011) suggest three types of possible government failures related to the
pharmaceutical sector: goals/priorities failure (wrong goals/priorities are chosen), policy
design failure, and implementation failure; these three types have been defined based on the
proposition to divide the governments’ actions into tree main stages and then evaluate
whether appropriate actions are made at each stage. Because lack of action is also a policy, I
would add to these three failures also failure to identify and define problems requiring
attention due to what nothing will be done to solve them.
Thus, I would define policy process for this capstone as all the actions (made or not
made/although were necessary by legislators and public officials from governmental
institutions) intended to identify/define problems and approve, implement and evaluate
pharmaceutical policy(s). It can be a system if actions are defined in some way and
relatively sustainable such as a pharmaceutical policy process suggested by WHO for NMP
or if it is a regulatory process used for approval of legislative documents through which a
country introduces its policies. However, if the efforts are chaotic and sporadic and lead to
nowhere, the way they are made cannot be defined as a system, although I would consider
them as a policy process because they include some stages of it, for example
developing/considering a policy proposal.
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According to WHO’s recommendations (WHO, 2001), NMP process includes three
main stages: formulation/development, implementation and monitoring. The development
process leads to formulation of NMP document; implementation means realization of
strategies and measures intended for achieving objectives/tasks on the basis of the plans
developed; monitoring and an evaluation allow to identify progress towards meeting
goals/objectives and, if necessary, to bring in appropriate correctives.
Roberts & Reich (2011) describe the pharmaceutical reform cycle as consisting of 6
steps: identifying problem, diagnosing the causes, developing a plan, getting political
approval, implementing, monitoring and evaluating. They suggest 5 “control knobs” as a
guide for the process of policy developing (financing, payment, organization, regulation,
persuasion). In his book Seiter (2010) tries to avoid any of the above mentioned two
frameworks; he replicates an order in which the World Bank diagnoses and addresses issues
- he uses stakeholder analysis to identify the actors and understand their motives and a
“pattern recognition” approach - to understand complex problems in the pharmaceutical
sector.
Why worry about Pharmaceutical policy process?
Understanding importance of the pharmaceutical policy process (PPP) is an
important lesson learned by the countries during a National Medicines Policy formulation
and implementation. It is difficult to expect good policy outcomes if process of policy
formulating, implementing and monitoring is not appropriately organized and managed. It
is also important to remember that there are certain factors (stakeholders’ interests, political
dynamics, the current situation in the pharmaceutical sector and other local conditions, etc.)
influencing PPP and being able to cause policy success or failure; so they should be taken
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into account and carefully addressed through appropriate strategies during policy process. It
is difficult to expect real progress in the pharmaceutical sector without ensuring that such
important activities as consultations and discussions, involving all interested parties,
collecting evidences, planning implementation, and others were incorporated in PPP. WHO
in particular stresses that a medicines policy “without an implementation plan remains a
dead document” (WHO, 2001, p.11).
According to MSH (2011), although PPP should be manageable yet few countries
have implemented all aspects of their policies successfully because of existing constraints.
The following factors are considered to be the main constraints: lack of political will, lack of
resources, opposition, and corruption; and the following are expected to be facilitating
factors: support of domestic and international interest groups, technical expertise, the
presence of committed people in the MoH, shared values (MSH, 2011).
Due to insufficient attention to PPP some countries have not been able to reach the
objectives established successfully, despite the fact that a NMP document has been
formulated and authorized. For example, the generics labelling and advertisement policy in
Thailand failed because of the resistance of the pharmaceutical industry; policy was aborted
despite a ministerial order for its promulgation (the Juridical Council ruled that the Order
was unconstitutional (Phanouvong et al. 2002). This example illustrates the importance of
involving all the main stakeholders, in this case - the pharmaceutical industry, in a process
of policy formulating. WHO suggests that “The policy process is just as important as the
policy document” (WHO, 2001, p.5). The analysis of the situation in Yemen where the
policy on creating an effective public pharmaceutical supply system failed in 2005 showed
that the revolving fund proposal has not been adequately implemented through a detailed
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implementation plan, the government had shown insufficient commitment to funding,
corruption took place and expected patients’ contributions were not realistic (MSH, 2011).
This example illustrates the importance of planning, government’s commitment, and
developing evidence-based policy that takes into account the results of local situation
assessment.
There are also known examples of success in implementing NMP when appropriate
strategies are used for providing good PPP. For example, the success of the implementation
NMP introduced in Lao P.D.R. is considered to be due in part of emphasis on operational
research; it was built in the pilot program in order to bridge gap between policy and practice
and to provide evidence for further policy making. Building the research component in
NMP made possible to monitor and evaluate implementation of pilot in five districts and
compare the results with control districts, to find out continuing problems and to use the
results of the research when revising NMP in 2001(MSH, 2011). Another well-known
example is collaborative approach used by Australia (Phanouvong et al. 2002, MSH, 2011).
In 1991 the Minister formed two advisory groups to involve all the interested parties to
contribute positively to the development and implementation of policy. After several years
of work in late 1999 a policy document taking into account elements of social and economic
policy was launched; it has four objectives based on active partnership. The policy also
recognizes a role of consumers and all partners have committed to consult with consumer
representatives. In 2010 the policy was still active (MSH, 2011). Consumers and other
partners continue to work together; in 2009 the first NMP Partnerships Forum was
organized to identify key areas where there is need for improvement and then they are
organized every year (Walsh, 2011). According to Walsh, a member of the Australian
14

National Medicines Policy Committee providing consumer expertise, “The policy can only
achieve its objectives and result in real benefits for consumers through partnership and
collaboration” (Walsh, 2011, p.2).
Based on the results of a special study entitled Medicines for All? The challenge for
developing and implementing national medicinal drug policies in Australia, Thailand, the
Philippines and Laos and implemented in Australia in late 90s authors suggested
considering five essential elements for effective policy implementation. They found out that
although successful implementation of NMP depends on many important prerequisites
“such as adequate funding, effective organizational structures, committed and qualified
human resources, and the recognition of the plurality of opinions” certain elements were
notable in experience of all countries studied. These elements were: “setting realizable goals
and objectives; political will and commitment on the part of governments; legislative and
regulatory frameworks; legitimacy; and the cooperation (and if necessary co-option) of
stakeholders” (Phanouvong et al. 2002, p.26).
According to authors, political will is one of the most important elements. They believe that
commitment should be provided not only on the part of the government, including the health
minister, the prime minister and the cabinet, but also by the main stakeholders because
success of policy depends on willingness and capability of the key players at all levels
including ministerial and parliamentary levels. Authors suggest reformers develop some
skill in mobilizing and convincing main government officials and political figures. Some
informants suggested that government officials should all be actively involved in the NMP
formulation process.
Some countries use numerous strategies to ensure appropriate PPP (Box 1).
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Box 1.
Thoroughly developed NMP process in Philippines
Six special strategies intended to overcome main problems and create consensus among partners were used in
Philippines at the stage of NMP formulating.
1.

Active use of consultations and participation. The Government took on the leading role in formulating
NMP. During the first year of developing policy two national meeting were organized; twenty five
documents were presented; ninety nine persons from sixty one organizations were involved. This strategy
created a sense of collective “ownership” of the planning reforms among all involved and increased their
readiness to defend policy.

2.

Institutionalization of policy through law and regulation. The law on generics of 1988 was the most
important one; it was approved in 18 months after NMP approval, included guidelines on main aspects
(generics, supply, formulary, etc.) and created a rear basis for NMP providing long term sustainability for
it.

3.

Formulating possibly comprehensive and practical policy. The working group used experience of other
countries and developed comprehensive policy covering 4 main components with the objective to provide
access to essential medicines.

4.

Involvement of the most qualified persons. It was planned that the policy is promoted by high level
officials included minister, several deputy-ministers, members of the working group which were selected
based on their high competence.

5.

Collection of adequate and evidence based data. Data collected by the working group provided support in
debates on NMP.

6.

Mobilization and use if international support. The support from WHO and some countries (Japan,
Australia) was important when policy was attacked within and outside the country.
Thoroughly developed and comprehensive process of policy formulating was necessary because policy

was intended to reform the pharmaceutical sector in whole.
Source: Quick J.D., 1997
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Authors who has slightly different from WHO’s approach to pharmaceutical policy also
emphasize importance of pharmaceutical policy process. When considering pharmaceutical
reforms intended to improve performance and equity, Roberts and Reich (2011) underline
that they “strongly believe that process influences both product and politics” (p.86).
Although the value of PPP is widely recognized and underlined in publications including
WHO and MSH guidelines (WHO, 2001; WHO, 2003, MSH, 2011), sufficient attention is
not always given to it. Lack of attention and, correspondingly, poor management of PPP can
be the result of very different factors, including insufficient understanding, lack of
knowledge, experience or motivation of the main participants, political dynamics. Good PPP
would assist not only in reaching better outcomes, providing a quicker solution of existing
problems, but also in ensuring the best use of resources.
Effectiveness of Pharmaceutical policy process
Based on the experience of countries described in the above-mentioned examples we
can suppose that success of the pharmaceutical policy depends on effectiveness of the
pharmaceutical policy process. In this capstone effectiveness means ability to reach
appropriate outcomes, in particular, for the pharmaceutical policy process it will mean that
policy(s) have been approved and implemented (law, regulation, programs, initiatives,
orders, etc.). It should not be confused with effectiveness of the pharmaceutical policy that
will mean that the policy objectives have been achieved (such as improved access to
medicines or their more rational use). To monitor progress of the pharmaceutical policy and
process towards to objectives different indicators/measures can be used. WHO has
developed different sets of indicators. The latest set - a core indicator package (three
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different levels) is intended for monitoring and evaluating country pharmaceutical
situations. It includes few indicators measuring the situation with NMP (WHO, 2007):
1.1. Is there a National Medicines Policy (NMP) document?
a) If yes, is it an official or draft document?
b) What year was it last updated?
1.2. Is there an NMP implementation plan that sets activities, responsibilities, budget
and timeline?
a) If yes, when was it last updated?
1.3. Is the NMP integrated into or included in the published/official national health
policy/plan?
a) If yes, when was the national health policy/plan last updated?
1.4. Has a national assessment/indicator study been conducted?
a) If yes, which topics have been studied and when was the most recent study covering
each topic conducted:
Overall pharmaceutical situation:
Rational use/prescription audit:
Access (i.e. prices, affordability and/or availability) to medicines:
1.5. Is there a code of conduct that applies to public officials and staff involved in
pharmaceutical related activities or posts, such as persons working in pharmaceutical
services, medicines regulation, procurement and supply of medicines and other
pharmaceutical divisions of the health ministry?
There is also a special set of indicators developed by WHO for monitoring NMP
(Brudon, 1994) which was published in 1994, however they are mainly intended to monitor
18

outputs and outcomes of policy implementation, not outputs and outcomes of policy process
itself.
However, WHO and MSH suggest certain recommendations related to the
pharmaceutical policy process which have been developed based on countries’ experience.
Based on these suggestions as well as my own experience I have developed the following
process and outcome indicators for the pharmaceutical policy process intended to define
whether PPP is effective and identify its strengths and weaknesses. Those process indicators
should not be confused with process indicators suggested by WHO for monitoring policy
during the process of implementation.
Process indicators
Stage of formulation:
 Responsibilities and time-frame for policy formulation are defined (the period for
preparing a draft should not exceed 6 months and overall time by the final
consideration should not exceed a year).
 Operational research is implemented to provide baseline data (not always applicable
for legislation/regulation documents).
 A policy paper on the issue considered is presented (should include brief description
of the current situation, evidence based policy options and be developed by experts).
 Stakeholder analysis is implemented.
 Draft of a final document is presented (if it is a policy document it should include
goals and strategies to achieve these goals; if it is legislation/regulation document, it
should include appropriate provisions).
 Legal basis for policy enforcement is ensured.
19

 Draft is made publicly available.
 A national conference/meeting is organized to present the final draft (all stakeholders
including patient/consumer organizations as well as media are invited).
 Strategies for political support are developed and implemented.
Stage of Implementation and Monitoring
 Draft of Implementation plan (can be called differently) is presented.
 Draft of evaluation program is presented.
 Drafts are circulated for consideration.
 Funding is provided.
 Mechanisms providing transparency and accountability are introduced.
 Draft of Implementation plan is formally approved.
 Draft of evaluation program is formally approved
Outcome indicators
Stage of Formulation
 Policy (policy or legislation/regulation document or program) is formally
approved.
Stage of Implementation and Monitoring
 All activities in the Implementation plan are implemented.
 The final evaluation document is presented and distributed.
Why worry about Pharmaceutical policy process in Armenia?
Despite the fact that the WHO suggested developing a comprehensive NMP as a written
document and Armenian experts and policy-makers were mainly agree with this approach,
there is still no officially approved NMP in Armenia. Although several drafts of a
20

comprehensive NMP document have been developed in Armenia since 1992 and considered
at different high levels (Ministry of Health, Ministry of Economy on behalf of the
Government), none have been formally approved. There is also no strategic plan on
improvement of the pharmaceutical sector in Armenia. Since 1992 some reforms have been
implemented, mainly in the early 90s. However some of them, for example privatization of
pharmacies, were not well prepared. Privatization and licensing of pharmacies were
implemented due to changes in the country’s economic system (transition to a marketoriented economy) in whole; however, necessary regulation to allow the pharmaceutical
sector to perform well under the conditions of the market-oriented system are still not in
place. Reforms related specifically to pharmaceuticals have been sporadic. The creation of
the Scientific Center of Drug and Medical Technologies Expertise (SCDMTE) in 1992 was
the most important of these reforms. SCDMTE was organized to carry out functions similar
to those of the Food Drug Administration in the U.S. (only on medicines, but not on food),
and several other functions. Because SCDMTE has a very well qualified staff of
professionals and access to resources (registration fees), the best improvements in Armenian
pharmaceutical sector were achieved in the area of drug authorization and related fields.
Several important strategies were initiated by the Ministry of Health; however, their
outcome is not really known due to absence of a system of monitoring and evaluation. The
current legislation is already obsolete and a draft of a new law has been under consideration
for 7 years. Regulation is still incomplete and there are no clear policies on pricing,
distribution, rational use of medicine and other important aspects related to medicines.
Although SCDMTE has developed a set of regulatory documents, they cannot be considered
until a new law is approved. A Value added tax (20%) was introduced on medicines (in this
21

case it was quite rapid decision) despite serious opposition. It has led to price increases. The
special social fund that was expected to be created based on the additional money flow
coming with the new tax has never been established. The fact that stakeholders have not
been involved in policy development and that there is no system to monitor implementation
of policy decisions have been major factors explaining policy failure.
Why compare the pharmaceutical policy process in the Newly Independent States?
The systems of medicines supply have changed significantly since 1992 in the NIS.
Although countries are now quite different in their size, social and economic level and other
characteristics, at the beginning of reforms in early 90s they had a very similar situation in
the pharmaceutical sector due to a common legislation and regulation, a common supply
system, the same education curriculum and so forth. After the collapse of the former Soviet
Union in 1991, the Independent States started reforms which were necessary to transform
the pharmaceutical system in a way it will be able to operate under the conditions of marketoriented economy. The speed and a content of reforms differed. These variances definitely
have led to differences in outcomes which have become more significant with the time
passing. At the beginning of 2000s differences between countries were observed with regard
to the structure of the sector, pricing and reimbursement systems, etc. (Drugs and Money,
2003, p.134). Now variations have become even more significant due largely to the different
socio-economic conditions achieved by countries. It can be said that the pharmaceutical
sectors of these countries are currently mainly established; however such challenges as a
lack of access to medicines, inappropriate use and some issues related to safety of medicines
still cause a concern in all the countries of the region. Countries continue their efforts to
improve medicines supply system and achieve the main objectives of the pharmaceutical
22

sector - providing the population of the countries with effective and safe medicines of
appropriate quality and their rational use. Appropriately formulated and approved National
pharmaceutical policy can make these efforts effective and improve outcomes. “In all CCEE
and NIS countries, continuing improvements in sector management should strengthen
recently established structures and create sustainability. National drug policies will continue
to play a stimulating strategic role.” (Drugs and Money, 2003, p.134).
There are only a small number of publications on the pharmaceutical policy process
from which lessons can be learned. There are certain recommendations developed by WHO
based on the countries’ experience that can be considered relevant to Armenia. There are
certain important recommendations related to PPP for improving policy implementation in
two very relevant recent publications of leading experts in this field - Roberts and Reich
(2011) and Seiter (2010). Their approaches differ slightly from those suggested by WHO.
Studying the experience on PPP of other Newly Independent States which went through a
transition process similar to the process that Armenia went through, seems to be very useful.
Goals and Objectives of this Capstone
The goal of this capstone was to analyze pharmaceutical policy process in Armenia and
other Newly Independent States and to develop recommendations for Armenia Research
questions:


What are the main challenges related to pharmaceuticals in Armenia?



What is the current pharmaceutical policy framework in Armenia?



What are strengths and weaknesses of pharmaceutical policy process in Armenia?



What are the similarities and differences in the pharmaceutical policy process in the
NIS and what lessons could be learn for Armenia?
23



What changes in pharmaceutical policy process in Armenia could make it more

effective?
The objectives are:


To review literature available on pharmaceutical policy process



To examine key elements of pharmaceutical policy process in twelve NIS countries:
existence of approved NMP document, participation of main stakeholders in its
development, existence of implementation plan and system for monitoring of NMP



To develop recommendations for improving the pharmaceutical policy process in
Armenia

Methods
Data and information were obtained from academic searches, Google search, search of
web sites of the World Health Organization, its Office for Europe, the Observatory (HiT
series), and various published and unpublished sources in NIS. Two interviews with key
informants were conducted – one from Armenia and one from Russia.

Part I. Pharmaceutical policy in Armenia
1. The main challenges in the Armenian pharmaceutical sector
Lack of access to medicines. Although total pharmaceutical expenditures increased
significantly during the last 20 years, they are still quite low when compared with other
countries. According to the Armenia Pharmaceutical Country Profile (2010), in 2008 the
total pharmaceutical expenditure per capita was AMD 7,030 (US$ 23). The total
pharmaceutical expenditure includes public spending (mainly provided from the State
Budget) and private spending (mainly out-of-pocket payments of patients). The rough
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estimates based on the results of analysis of data received from the annual Integrated Living
Conditions Survey of Households (ILCS) suggest that the total out-of-pocket expenditures
on medicines per capita per year consisted of about 21 USD in 2008 and 2009, and then
sharply increased totaling 37 USD in 2010. The share of spending on medicines also
increased in 2010 and totaled 4% of the total expenditures of surveyed households (3.3% in
2009 and 1.8% in 2008). This sharp increase in pharmaceutical spending is not supported by
the data on imports for 2008, 2009 and 2010 that vary with the biggest value in 2008
(Foreign trade, 2009, 2010, 2011) and can be only partly explained by price increases.
Expenditures on pharmaceuticals per household member depend on family income.
In 2010, out-of-pocket expenditures on medicines per member of non-poor households
(49USD per capita per year) were 3 times higher than those of the poor (16USD per capita
per year) and around 8 times higher than of those extremely poor households (6USD per
capita per year). This clearly shows that individuals from families with low income have
very limited access to medicines. Although there is a pharmacy reimbursement system in
place that covers certain social groups and patients with certain diseases (children under 7,
disabled persons, etc.), the list of social groups does not include individuals from families
living in poverty.
Public pharmaceutical expenditures are also very low in Armenia. According to the
Report on implementation of the State Budget of the Republic of Armenia for 2011, the total
public pharmaceutical expenditures of 4.1 billion Armenian drams is about $11 million or
3.4USD per capita per year. Two recent studies have shown that this is not enough to cover
needs of even a restricted population eligible for receiving medicines free of charge or with
discounts. The study by the Economic Development and Research Center (EDRC) has
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shown that more than 40 percent of sick people mentioned that they received only 10
percent of medicines needed for treatment. Only 45 percent of households who have
members from any social group or disease eligible to receive drugs with privileges,
exercised their rights (EDRC, 2011). According to the data of the Drug Utilization Research
Group (DURG) that implemented study among households in all the regions of Armenia in
2011, patients with certain diseases eligible to receive pharmaceuticals free of charge got
only 23% of the free medicines they used during the last 2 weeks, in particular less than
25% of medicines for children under the age of 7 were provided for free (Melikyan, 2011).
During the study in 2008 “Health officials acknowledged that allowances to polyclinics for
adult drugs were inadequate, and many patients entitled to free outpatient drugs were forced
to purchase them in the market.” (PHCR, 2010, p.7).
Because the majority of patients pay for medicines out-of-pocket, pharmaceuticals
are not affordable for many individuals and families. The 2008 survey has shown that
approximately one third of the surveyed households did not get a recommended service after
they contacted the health system; in particular for medicines, 35% of those who did not get a
recommended service said they failed to do so “because of finances” (PHCR, 2010). In
August 2009, many households reported foregoing medications due to financial difficulties,
in particular 21% reduced or stopped buying the medicine they required (WFP, 2010).
“Most households did not seek health care or did not purchase prescribed medicines for lack
of income to cover the cost” (World Food Programme, 2010, p.32). Although private
pharmaceutical expenditures increased in 2010, only 50 % of representatives of households
studied noted that they can usually afford to buy all the medicines they need (Melikyan,
2011).
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High prices are one of the main factors affecting the affordability of medicines and
treatment. Very large differences in prices of originator brand products (and brand name
generics) and the lowest-priced generics lead to different affordability of these products. For
example, the number of days the lowest-paid government worker needs to work in order to
be able to pay for a standard course of treatment for arthritis (diclofenac, 50 mg capsule or
tablet) is 10.8 days if originator brand product is used and 0.78 day for the lowest-priced
generic (Kazaryan, 2011). It should be noted that physicians often prefer to prescribe
originator brand products or brand name generics.
Irrational use of medications. Although there is a lack of research on medication use in
Armenia, inappropriate use of pharmaceuticals can be easily predicted based on the
existence of the majority of factors known to lead to misuse of medicines, in particular, lack
of updated treatment guidelines or their monitoring, inadequate knowledge among
professionals and population, unrestricted distribution of Prescription Only Medicines
(POM - medicines which can be dispensed only if prescription is available) from pharmacies
despite an appropriate provision in the law on medicines, aggressive promotion by
pharmaceutical companies and so forth. The results of household surveys have shown that
68% of POM used by any of household’s members during the previous 2 weeks, including
antibiotics, were bought without prescription (Melikyan, 2011). Another study has shown
that only 58.5% of antimicrobial medicines sold by pharmacies in Yerevan were prescribed
by physicians, 10.5% were advised by pharmacist/technician, 31% - by other persons;
77.2% of prescription only antimicrobials were sold without prescription (Hakobyan, 2011).
The essential medicines list (EML) was firstly introduced in Armenia in 1992 and was
updated on a regular basis until 2007. However after 2007, a revised version was not
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approved. In 2006, a new mechanism requiring physicians to prescribe medicines from
EML to patients covered by the reimbursement system was introduced. However, physicians
continue to prescribe pharmaceuticals out of the EML. Analysis of medicines used by
members of households studied shows that only approximately 43% of medicines were from
the EML (Melikyan, 2011).
Although clinical guidelines for the most primary health care diseases were
developed and approved in early 2000s, the majority of them have not been updated. The
study in 2006 showed that prescribing practices vary widely among providers. Treatment
guidelines were not available at all facilities studied and actual prescribing practices for
studied conditions varied significantly from treatment recommendations (Lee, 2007).
2. Brief history of Armenian pharmaceutical reforms
Early years
In 1992, after the proclamation of independence, the Republic of Armenia started to
formulate its own pharmaceutical policy. Recommendations of the WHO, as well as local
conditions were taken into account as the basis for policy development. Armenia was faced
with the need to implement comprehensive pharmaceutical reform covering almost all the
components of the pharmaceutical sector. The early years were very successful. In 1992, the
Government established the Armenian Drug and Medical Technology Inspection (then it
was renamed and called SCDMTE, and then renamed again as the Scientific Centre of Drug
and Medical Technology Expertise - SCDMTE), which was partly modeled on the United
States Food and Drug Administration (FDA) (Hakobyan, 2006) taking into account the
recommendations of WHO for small countries and local conditions. SCDMTE (then Drug
Inspection) was the first organization with National Drug Regulatory Agency’s functions
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created in the Newly Independent States. Before that time all medicines evaluation and
authorization functions had been managed by a single set of institutions in Moscow.
Armenia created a new system for medicines evaluation and registration soon after
independence, creating the opportunity for the country to authorize medicines and control
their quality on the pharmaceutical market. SCDMTE was also responsible for licensing and
inspecting producers, wholesalers and pharmacies, monitoring drug adverse reactions and
some other functions. A new laboratory was also created at SCDMTE with support of the
Gulbenkian Foundation. The new laboratory was supplied with modern equipment and
became the best equipped quality control laboratory at the Drug Regulatory Agencies
created on the territory of the former USSR.
SCDMTE proposed to the Ministry of Health that it should adopt the Essential Drugs
concept recommended by WHO as the basis for national policy on medicines. As the result,
in 1992 the first version of Armenian Essential Drugs List (EDL) and some corresponding
strategies were approved by a special Decree of the Minister of Health. After long
consideration a draft of the first law “on medicines” was approved in 1998. It was developed
by SCDMTE in 1994 and then was discussed with some stakeholders including the Ministry
of Health, other ministries, and the Armenian pharmaceutical association.
The former state “Armpharmacy” Republic Association which comprised all the
pharmacies and one warehouse in Armenia was reformed. All pharmacies were privatized
and numerous new private pharmacies were founded and licensed which created the
opportunity for increasing the availability of medicines. In 1993 the Department of
Pharmacy was established at the National Institute of Health for providing continuing
education for Armenian pharmacists.
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The success in reforming the pharmaceutical sector in Armenia during the early years of
independence was possible due to some important factors: leadership by the Head of
SCDMTE, high level of motivation and high competence of SCDMTE’s staff (the best local
professionals were involved); relying on evidences as much as possible (the most of the staff
were researchers) when developing policy suggestions, political will provided by the
Ministry of Health.
Recent years
The Ministry of Health has introduced system of reimbursement based on the Essential
Medicines List (MoH, 2006) and some other initiatives. Some strategies intended to
improve national security in the area of Health care and, in particular in the pharmaceutical
service, were approved by the appropriate Government Decree (RA Government, 2010a).
The USAID-funded Competitive Armenian Private Sector (CAPS) project together with
local manufacturers initiated the development and approval of regulations on Good
Manufacturing practice (RA Government, 2010b) and some other documents important for
development of pharmaceutical industry in Armenia.
In 2012 the Government formally recognized and addressed some urgent challenges in
the pharmaceutical policy, including ineffective centralized and not centralized
procurement, lack of state control in the Health care system, and ineffective system of
medicines evaluation (RA Government, 2012).
3. National medicines policy document in Armenia
Drafts of National medicines policy document and their content
Armenia’s first NMP document - “Concept of a program of the pharmaceutical sector
development in the Republic of Armenia” appeared in 1993 (Kazaryan & Melikyan,
30

1998/99). It was based on the WHO recommendations and the local situation. The document
was comprehensive and included the following sections: introduction (problems in the
sphere of medicines supply and their reasons, the aim and tasks - long-term and mid-term
for the first five years' period); the main principles of public policy in the pharmaceutical
sector at the early stage (1993-1997) - separately for nine components; the brief
characteristics of resources; the main mechanisms of NMP implementation (strategies) for
the first stage – again separately for nine components; structure of pharmaceutical
management (a scheme of management, units responsible for each of mechanisms); plan of
implementation (for 1993-1997) . The main components determined were the following:
legislation, policy and management, pharmaceutical industry, medicines supply, rational
use, quality assurance, research, human resources, and information. In fact, the Concept was
a first draft of NMP for Armenia. The document was developed by the group of leading
experts based on detailed assessment of the current situation and opportunities for
development. A draft was successfully approved by the Ministry of Health and then by the
Ministry of Economy on behalf of the Government (Kazaryan & Melikyan, 1998/99).
However, due to political changes in the Government and changes in policy development
approaches in the country, the developed document has never become an official strategy.
The next drug policy development was the “Document of Armenian National Drug
Policy” that emerged in 1995. The document included the following sections: introduction;
objectives and tasks, NMP elements and guidelines for their introduction (ADMTA 1995;
GPHCDP 2006). Although this document was not approved by any formal authority in
Armenia and, correspondingly, could not be considered an official NMP document that is
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obligatory for implementation by other organizations in the country, it became a very good
guide for further activity of SCDMTE that started to implement strategies described there.
In early 2000s, two different drafts of NMP were developed to become a part of
National Health Policy document and submitted to the Ministry of Health. A draft submitted
by NGO DURG included a brief assessment of the current situation, goals, objectives and
strategies intended to solve main problems revealed from the assessment. Strategies were
developed for all components suggested by WHO for NMP document.
The last data available about the NMP document comes from the Armenia
Pharmaceutical Country Profile (Armenia Pharmaceutical, 2010) that states “The National
Health Policy Document is a draft. The NMP is a part of this document” (p.41). This means
that NMP was formulated as a part of a draft of the National health policy document
however the latest is still a draft because has not been approved yet. The Armenia
Pharmaceutical Country Profile also informs that the draft was updated in 2006. Because the
Profile was submitted in 2010, it is evident that the draft has not been approved yet at that
time and we have to assume that there were no officially approved NMP in the country in
2010.
Thus, despite numerous efforts, Armenia does not have a formally approved
comprehensive National Medicines Policy document.
Formulation of NMP document
The process of NMP formulation began in Armenia in 1992 when the Government
charged the ministries to design the concepts of corresponding sectors development. MoH
started developing two documents: the concept of a program of health care development and
the concept of a program of pharmaceutical sector development. Two working commissions
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of experts were created. The working group on the pharmaceutical service development
consisted of representatives of various sectors: research institutes of the Academy of
Sciences and the MoH, the state enterprise, “Armpharmacy” at MoH, and the State Medical
University. An economist (expert at the Standing commission on health care and social
affairs at the Supreme Council of Armenia) was also included in the working group. The
vice-president of SCDMTE was selected to be the Chairman of the working group. The
group worked under supervision of the Chairman of SCDMTE; all the activities were
implemented on voluntarily basis. A detailed analysis of the pharmaceutical sector was
carried out, and the results were submitted as a separate detailed review. A draft of the
document “Concept of pharmaceutical service development in RA” was developed. Works
in progress and drafts were discussed at meetings at MoH and the meeting of the Ministry of
Economics Board when a draft was approved on behalf of the Government. The whole
process took about one year.
The “Document on a National medicines policy of RA” produced in 1995 was
formulated by SCDMTE’s staff. It was considered and approved at the joint meeting that
took place in SCDMTE with participation of representatives of various interested parties of
the pharmaceutical sector: MoH RA, SCDMTE, and the WHO Regional Office for Europe.
The third time the issue of a NMP document was on the policy agenda was in 2002 –
2003. The MoH RA initiated the development of a health policy document. It was planned
that document would be approved by a Resolution of the RA Government and become a
guide for the sector’s development. One of chapters of a document was planned to cover the
issues related to supply of medicines (in fact NMP). Two independent drafts covering
pharmaceutical policy issues were submitted to the MoH. One of them was presented by the
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Armenian nongovernmental organization, “Drug Utilization Research Group” (“DURG”). A
draft was developed on the basis of a detailed assessment of the pharmaceutical sector
(Kazaryan 2003) and included interviews with representatives of various Ministries, in
particular, Economics and Finance, Industries and Trade, Social Affairs, as well as
professionals from the National Institute of Health, pharmaceutical associations, and
consumer organizations. This draft was discussed with representatives of WHO and
international experts from the Department of Public Health at the London School of
Hygiene and Tropical Medicine. Another draft was developed by SCDMTE. A draft health
policy document was discussed at several meetings organized by the MoH RA with some
interested parties.
Implementation and monitoring of NMP
Because no draft was formally approved and adopted, there has been no plan
implementation. However, SCDMTE started implementing some important strategies and
tried to promote them through MoH. For example, the EML has been regularly updated.
Standards Treatment Guidelines for many diseases have been developed.
From 31st May till 1st July, 2001 a special meeting took place in SCDMTE that was
dedicated to analysing SCDMTE’s activities to implement a medicines policy since 1994 by
the SCDMTE and MoH in a close cooperation with the Regional Office for Europe. More
than 60 persons, including representatives of the various interested parties, attended the
meeting. The special report was developed and distributed (ADMTA, 1995).
4. Pharmaceutical policy framework
According to the World Health Organization’s approach, a National Medicines Policy is
“a comprehensive framework in which each component plays an important role in achieving
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one or more of the general objectives of the policy” (WHO, 2001, p.6). WHO suggests the
following main components: selection of essential medicines, affordability, financing
options, supply systems, regulation and quality assurance, rational use, research, human
resources, monitoring and evaluation and also provides the key policy issues for each
component (WHO, 2001; WHO, 2003). Although there is no approved NMP document in
Armenia, some important policies have been adopted through legislation and regulatory
documents. There are two types of documents: legislative (laws approved by the National
Assembly) and sub-legislative (Government Resolutions and Decrees of Ministers approved
by the Ministry of Justice). Assessment of the current pharmaceutical policy framework in
Armenia in this capstone is conducted by identifying whether key pharmaceutical policy
issues recommended by the WHO are approved or, although not approved, are implemented
in Armenia (Table 1). The set of key policies, listed in the WHO issue of the Policy
Perspectives on Medicines series “How to develop and implement a national drug policy”
(WHO, 2003) was used for this assessment.
The data presented in the table 1 indicate that although many key policies are approved
and implemented in Armenia, some of them have not been adopted. According to this
assessment 17 of 44 policies recommended by WHO are approved and additional 11 are
implemented although are not formally approved. It is important to increase the number of
approved and implemented policies in order to improve medicines use. A special study was
recently implemented to demonstrate evidence of NMP effectiveness (Holloway, 2012).
Authors have had the objectives to determine whether medicine use is better in those
countries with certain pharmaceutical policies compared to those without and whether
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medicines use improves with increasing number of policies. The results have demonstrated
that the more policies are implemented, the better the drug use.
The results of this assessment show that policies are mainly introduced through
legislative and sub-legislative documents (Law “On Medicines”, certain RA Government
Resolutions and Decrees of the Minister of Health). In 2012, a program aimed to solve
certain problems in the pharmaceutical policy was approved as a policy document by the
Government (Government, 2012). Some policies, although not adopted, are implemented,
mainly by the staff of SCDMTE. Currently, the results of this practice are positive because it
allows Armenia to achieve certain important outcomes. For example the (unapproved but
adopted) use of the effective medicines selection process and objective selection criteria
provide the opportunity to ensure development of appropriate EDL. However, it is important
that such practice be changed and appropriate policies be introduced to provide
sustainability and decision-making that is independent from personal ethical and
professional preferences of the SCDMTE staff.
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Table 1. Status of key pharmaceutical policies in Armenia

Selection of essential medicines
Key policies suggested by
WHO
Adoption of the essential
medicines concept to
identify priorities for
government involvement in
the pharmaceutical sector

Policies existing in Armenia
The essential medicines concept was
accepted from the first years of
Independence. The first List of Essential
Medicines (EML) in Armenia was
authorized in 1994. It is periodically
updated (mainly every 2 year until 2007;
the last approved EML is of 2007 as
developed drafts were not approved;
currently a new draft is developed and
three is command from MoH to speed the
process).
Law “On medicines” (Article 18) states
that availability and affordability
medicines from EML is ensured in the
Republic of Armenia.

Selection of essential
medicines in a two-step
process: (1) market
approval; (2) selection of
essential medicines relevant
to the national morbidity
pattern
Defining the selection
criteria (i.e. sound and

Corresponding
document and its link
Law “On medicines”,
1998 (Article18)
English version is
available at
http://pharm.am/files/juris
tdocs/20080306_151440_
en_drug_law.pdf
The last EML was
approved by the Decree of
the Minister of Health N
854-N of May 16th, 2007.
http://pharm.am/basis.php
?pg=5&langid=1

Notes about policies that are not
approved or do not exist
Although the concept is accepted
and commitment is stated in the
Law, mechanisms necessary for
implementing the concept, are
mainly not developed; the only
exception is requirement to prescribe
medicines from EML to patients
who receive medicines free or with
privileges.
Also, SCDMTE ensures a priority
registration for the essential
medicines.

There is currently no formally
approved policy on selection
process. However, the staff
currently involved in the process of
selection, try to follow these and
other important principles for
selecting medicines for EML
There are no currently formally
approved selection criteria.
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adequate evidence, costeffectiveness, etc.)

Defining the selection
process (i.e. appointment of
a standing committee, etc.)

A special committee - Pharmacological
Commission responsible for selection of
medicines for EML and other related
issues, is appointed at MoH

RA Minister of Health
Order N 965 of 2006
(there is no link available)

Ensuring a selection
mechanism for traditional
and herbal medicines.

However, the staff, currently
involved in the process of selection,
try to follow recommendations of
WHO for selecting medicines for
EML; Armenian EML is mainly
based on the WHO Model EML and
local morbidity data
There is only policy on the
Pharmacological Commission, but
not other aspects of selection
process
Only products that can be defined as
a “medicine” are considered for
including in EML. Traditional and
herbal products can get a “medicine”
status only if they are evaluated and
authorized like other products. Thus,
there is no need for a separate
mechanism.
It is not an issue for Armenia
because modern medicines are used
in a great majority of cases.

Affordability
Key policies suggested by
WHO
Government commitment to
ensuring access through

Policies existing in Armenia

Corresponding
document and its link

Notes about policies that are not
approved or do not exist
There is no such commitment
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increased affordability
For all medicines: removal
or reduction of taxes and
tariffs on essential
medicines; control of
distribution margins; pricing
policy

Since 2001there is a 20% VAT
(until 2000 medicines were exempt
from VAT) (Hakobyan, 2006).
There is neither control of
distribution margins nor any pricing
policy. There are no duties on
imported raw materials or on
imported finished products.
(Armenia Pharmaceutical, 2010).
There is no a special generic policy.

For multi-source products
(generic medicines and
branded generics):
promotion of competition
through generic policies,
generic substitution and
good procurement practices

For single-source products:
price negotiations,
competition through price
information and therapeutic
substitution, and TRIPScompliant measures such as
compulsory licensing, “early
workings” of patented
medicines for generic
manufacturers and parallel
imports.

Current laws contain (TRIPS) flexibilities
and safeguards (not specified for
medicines (Armenia Pharmaceutical,
2010).

Generic substitution is not regulated
(there is no any special provision,
but generic substitution is
traditionally used because it was
allowed by the soviet time
regulation).
There is no good procurement
practice policy on medicines.
Law “On inventions,
There is no policy on price
utility models and
negotiation or competition through
industrial designs” of June price information and therapeutic
10th, 2008
substitution.
http://www.parliament
.am/legislation.php?sel=sh TRIPS safeguards have never been
ow&ID=3324&lang=arm used.
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Financing options
Key policies suggested by
WHO

Policies existing in Armenia

Corresponding
document and its link

Notes about policies that are not
approved or do not exist

Commitment to measures to
improve efficiency and
reduce waste

There is a general policy on efficiency of
centralized procurement. According to
Law “On procurement” the State agency
on procurement organizes centralized
procurement (mainly through tenders) of
certain goods including medicines, those
are determined by the MoH; Agency also
carries out tenders for individual health
facilities (Armenia Pharmaceutical, 2010).

Law “On Procurement” of
December 22th, 2010
http://www.parliament
.am/legislation.php?sel=sh
ow&ID=3985&lang=arm
&enc=utf8 (in Armenian)

There are still no clear requirements
to medicines’ procurement that
correspond to Good procurement
practice.

In 2012, a new approach to providing
efficiency in procurement of medicines
was approved.
There is a policy to restrict
reimbursement to EML (medicines in
EML are listed under generic names).

Decision of RA
Government meeting “On
approval of program on
solving problems in state
control in the area of
Health care, as well as in
pharmaceutical policy;
and list of measures
ensuring implementation
of program” of October
18th, 2012 (protocol 42)
http://www.moh.am/?secti
on=static_pages/index&id
=214

It is accepted now (Government,
2012) that practice of medicines
procurement (both centralized and
not centralized) is very inefficient.

RA Minister of Health
Order N 74-N of January
27th, 2005 “On adopting
the order of free or
privileged provision of
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medicines”
http://pharm.am/jurdocs_li
st.php?pg=3&id=4&langi
d=2 (in Armenian)

Increased government
funding for priority
diseases, and the poor and
disadvantaged

Medicines for some diseases and for
patients from certain social groups are
provided free of charge or with privileges

Promotion of medicine
reimbursement as part of
public and private health
insurance schemes
Use of user charges only as
a temporary drug financing
option

Limiting the use of
development loans within
identified national priorities
Following national or WHO
guidelines for medicine

RA Government
There is no policy on funding
Resolution N 1717-N of
medicines for poor, pregnant and not
November 23rd, 2006 “On disadvantaged elderly
adopting the list of
diseases and social groups
of population entitled to
free or privileged
purchase of medications”
http://pharm.am/jurdo
cs_list.php?pg=3&id=2&l
angid=2 (in Armenian)
There is no public insurance, only
voluntary private insurance (very
small % of population); there is no
special policy on medicines
There are no user charges. The
majority of medicines are bought
out-of –pocket; those that are
reimbursed – are provided to
patients for free or with 50% or 30%
discount
There is no special policy; however,
loans are not used for funding
medicines

There is a policy on donations that
correspond to WHO guidelines
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donations
Supply system
Key policies suggested by
WHO

Policies existing in Armenia

Corresponding
document and its link

Promoting a public-private
mix in medicine supply and
distribution systems

All pharmacies and wholesalers in
Armenia are private. There is only
one public warehouse responsible
for distribution of donations
There are no any special provisions
covering procurement of medicines,
including those suggested by good
pharmaceutical procurement practice
There is no special policy requiring
publishing prices. Some wholesalers
publish medicines’ prices
voluntarily.
There are no special provisions.

Committing to good
pharmaceutical procurement
practices in the public sector
Publishing price information
on raw materials and
finished products
Ensuring medicine supply
systems in acute
emergencies
Carrying out inventory
control, and taking measures
for prevention of theft and
waste
Ensuring disposal of
There is a special policy in place covering
unwanted or expired
rules on disposal of medicinal products
medicines
and pharmaceuticals.

Notes about policies that are not
approved or do not exist

There is no special policy. However,
being private all wholesalers and
pharmacies take their own measures.
“Law on waste” and Order
of the Minister of Health
N 03-A of March 4, 2008
“On adopting sanitary
rules and norms N 2.1.3-3
“Hygienic and anti-

It was a serious problem for
Armenia as a huge amount of
expired medicines were kept in the
country after receiving donations
due to Earthquake in 1988.
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epidemic requirements to
the usage of medical
wastes in RA”.

There is no policy on collection and
disposal unused medicines from
patients.

Corresponding
document and its link

Notes about policies that are not
approved or do not exist

Regulation and quality insurance
Key policies suggested by
WHO
Government commitment to
drug regulation, including
the need to ensure a sound
legal basis and adequate
human and financial
resources
Independence of the
regulatory authority to
ensure that there is no
conflict of interest

Commitment to good
manufacturing practices,
inspection and law
enforcement

Policies existing in Armenia

There is no a special statement about
such commitment

Some functions of Drug regulatory
authority (DRA), including medicines
evaluation, quality control and some
others are implemented by SCDMTE – a
special organization at MoH. It is
independent because mainly has
evaluation functions; it is not responsible
for any function related to medicines
supply.
Good manufacturing practice (GMP) was
introduced in 2010 by approval of a
Government Decree.
Policy on inspection was approved by the
RA Government meeting in October
2012.

There is no legislation or
regulatory document
clearly defining
responsibilities and
functions of SCDMTE.

RA Government Decree N There is no detailed/specific policy
1603-N of November 25th on law enforcement in the case of
, 2010 “Rules of Good
incompliance with GMP standards
Manufacturing Practice”
http://www.moh.am/?s
ection=static_pages/index
&id=586&subID=617 (in
Armenian)
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General statement on “Responsibility for
the violation of drug preparation and
manufacture order” is included in the Law
“On medicines”

RA Government Decree N
734-N of May 26th, 2011
on “Approval of timeline
for introducing rules of
GMP in RA and
implementing reforms in
the pharmaceutical
sector”.
http://www.pharm.am/file
s/juristdocs/20110622_17
4340_am_gamanakacujc.p
df
Decision of RA
Government meeting “On
approval of program on
solving problems in state
control in the area of
Health care, as well as in
pharmaceutical policy;
and list of measures
ensuring implementation
of program” of October
18th, 2012 (protocol 42)
http://www.moh.am/?secti
on=static_pages/index&id
=214
Law “On medicines”
(Article 7)
http://pharm.am/files/juris
tdocs/20080306_151440_
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Regulation of traditional and Some aspects related to herbal medicines
herbal medicines
(licensing requirement for culturing and
sale medicinal herbs) are regulated

Ensuring adverse drug
reaction monitoring systems

There is policy on adverse drug reaction
(ADR) monitoring system – the statement
in Law.

Commitment to regulation
of information and drug
promotion

There is detailed policy on medicines
information and promotion covered by
two laws and specific regulation
document

en_drug_law.pdf
Law “On medicines”
(Article 3)
http://pharm.am/files/juris
tdocs/20080306_151440_
en_drug_law.pdf
Law “On medicines”
(Article 17)
http://pharm.am/files/juris
tdocs/20080306_151440_
en_drug_law.pdf
RA Law “On
medicines” (Article 11)
http://pharm.am/files/juris
tdocs/20080306_151440_
en_drug_law.pdf

There is no special regulation on
traditional medicines

Although there is only one sentence
in the law, a system works well. A
national Pharmacovigilance center
exists at SCDMTE (Hakobyan,
2006)

RA Law “On advertising”
http://pharm.am/jurdocs_li
st.php?pg=3&id=1&langi
d=2 (in Armenian)
RA Government Decree N
1608-N of November 2,
2006, “On adopting the
order of granting
permission to advertise
medicines, medical
equipment and methods of
treatment and
requirements made to
these advertisements”
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http://pharm.am/jurdocs_li
st.php?pg=3&id=2&langi
d=2 (in Armenian)
International exchange of
information

Rational use
.
Key policies suggested by
WHO
Mandated multidisciplinary
national body to coordinate
medicine use policies
Development of clinical
guidelines as the basis for
the selection of essential
medicines and training of
health professionals

Problem-based training in
pharmacotherapy in
undergraduate training
Continuing in-service
medical education as a
licensure requirement

There is no special policy on this
issue for medicines; however
Armenia provides information to
WHO in scopes of International
agreements

Policies existing in Armenia

Corresponding
document and its link

Notes about policies that are not
approved or do not exist
There is no such policy in place.

There is no any approved policy on
clinical guidelines. However, it is
valued by SCDMTE and, currently,
by MoH. In early 2000s around 40
clinical guidelines were developed
under supervision of SCDMTE,
however some are already obsolete.
There is no special policy, however
problem-based training is provided
(Armenia Pharmaceutical, 2010)
Continuing education is required, however RA Government Decree N In practice this requirement often
not as a licensure requirement, as there is
867 of June 29th, 2002 of
ignored.
currently no licensing system for health
29.06.2002 on “Rules on
professionals in place
Licensing Production of
Medicines, Pharmacy
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Independent and unbiased
medicine information

Issue of medicine information is slightly
covered by
Law “On medicines”

Practice, Health Service,
Implementation of
Medical Professional
Education Curricula, as
well as on Approve of
Licensing Forms for
Implementation of
Mentioned Activity”.
http://www.pharm.am/
jurdocs_list.php?pg=3&id
=2&langid=2
Law “On medicines”
(Article 11)
http://pharm.am/files/juris
tdocs/20080306_151440_
en_drug_law.pdf

Public education about
medicines

Two Formularies (containing
unbiased medicine information, not
just lists of medicines) were
prepared by SCDMTE staff and
published, the latest in 2010.
There is no special policy. SCDMTE
sometimes implement public
education campaigns.
There is no special policy.
Unfortunately, in practice such
initiatives are successfully used.

Avoidance of perverse
financial incentives to
prescribers and dispensers
Research
Key policies suggested by
WHO
Operational research in
medicine access, quality and
rational use

Policies existing in Armenia

Corresponding
document and its link

Notes about policies that are not
approved or do not exist
There is no such policy, some
organization initiate such research
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Drug development and
clinical research

There is special policy on clinical trials.

RA Law “On medical aid Approved requirements only partly
and population services”
cover set of requirements suggested
of May 4th, 1996
by the majority of GCP rules
http://www.moh.am/?s
ection=static_pages/index
&id=235&subID=59
(in Armenian)
RA Government Decree N
63 of January 24th, 2002
“On Rules on
Implementation of
Clinical trials of new
medicines in the Republic
of Armenia”.»
http://pharm.am/jurdo
cs_list4.php?pg=16&id=2
&langid=2 (in Armenian)
RA Minister of Health
Order N 05-N of 17 May,
2011 “To approve the list
of required documents for
obtaining authorization to
conduct clinical trials and
the statute of the ethics
committee.”
http://pharm.am/jurdo
cs_list4.php?pg=16&id=2
&langid=2(in Armenian)

Human resources development
48

Key policies suggested by
WHO

Policies existing in Armenia

Corresponding
document and its link

Notes about policies that are not
approved or do not exist

Government responsibility
for planning and overseeing
the development, training,
team building and career
planning of human
resources needed for the
pharmaceutical sector

There is a policy on licensing
implementing Medical Professional
Education Curricula

RA Government Decree N There is no special policy on
867 of June 29th, 2002 of
development human resources for
29.06.2002 on “Rules on
the pharmaceutical sector
Licensing Production of
Medicines, Pharmacy
Practice, Health Service,
Implementation of
Medical Professional
Education Curricula, as
well as on Approve of
Licensing Forms for
Implementation of
Mentioned Activity”.
http://www.pharm.am/
jurdocs_list.php?pg=3&id
=2&langid=2

Definition of minimum
education and training
requirements for each
category of staff
The need for external
technical cooperation
(national and international)

There are certain requirements on
education for those who is implementing
pharmaceutical service.

See above-mentioned RA
Government Decree N
867.
There is no policy approved,
however, there is an active
cooperation with the WHO Special
Project for
Pharmaceuticals in NIS at the WHO
Office for Europe
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Monitoring and evaluation
Key policies suggested by
WHO
Explicit government
commitment to the
principles of monitoring and
evaluation
Baseline survey of the
whole country carried out
early in the implementation
of the policy
Monitoring of the
pharmaceutical sector
through regular indicatorbased surveys

Independent external
evaluation of the impact of
the policy on all sectors of
the community and the
economy, preferably every 2
to 3 years

Policies existing in Armenia

Corresponding
document and its link

Notes about policies that are not
approved or do not exist
There is no any policy on
monitoring and evaluation

Never implemented by authorities.
Some survey were implemented by
NGOs with funding of International
organizations
The one-time assessment (notindicator-based) was initiated by
SCDMTE in 2001.
An indicator-based assessment was
carried out by NGO called “DURG”
in 2002
There is no such policy
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Many important key policies were introduced through provisions for the Law “On
medicines” of 1998. The law covers the following areas: pharmaceutical activity and its
licensing, manufacturing, labelling, import and export, information, advertisement, destruction,
registration, quality assurance, state guarantees of medicines ensuring to population and some
others. However, all policies which are stated there, describe the main approaches very briefly in one or few sentences. According to this law more than ten regulatory documents should be
developed and introduced by the Government and the Ministry of Health in order to provide
detailed requirements and procedures. Only some of these exist as drafts (labelling, state
guarantees of medicines ensuring to population and some others).
The results of this assessment also show that the number of policies introduced in the
different components varies (Table 2). The best ratio of approved to recommended policies is
observed in the area of Regulation and Quality Assurance (5 of 7) while the no policies have
been developed on Monitoring. Only a few policies are available in the fields of Affordability
and Rational Use. This is especially alarming because a lack of access to medicines and
inappropriate use are among the most important challenges in Armenia.
Although a special policy on antibiotics was not included in the list of key policies used for
assessment, it is necessary to mention that this area currently cause a great concern however is
not covered by any policy or regulation document.
The results of this assessment concerning differences in numbers of approved policies among
the various components are consistent with the opinion of a key informant from Armenia who
indicates that introducing systems ensuring quality and safety of medicines is a strength of
Armenia’s policies while the absence of systematization and interlinked activities especially
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among those aimed to provide access to medicines and improve rational use are the weaknesses
of pharmaceutical policy in the country.
Table 2. The number of key policies on pharmaceuticals approved in Armenia, by
components
Component

Number of
key policies
recommended
by WHO
(WHO, 2003)

The total
number of
those
recommended
by WHO key
policies which
are approved
in RA
including onesentence
provisions
2

The
number of
clearly
defined and
described
key
policies

Number of
approved
policies
which are
implemented

Number of
not-approved
policies
which are
implemented
as initiatives

Selection of
Essential
Medicines
Affordability

5 (1 of 5 is
not applicable
for Armenia)
4

0

2 (1 –partly)

2

0

0

1

6

1 (not specific
for medicines)
3

Financing
options
Supply
System
Regulation
and Quality
Assurance
Rational use
Research
Human
resources
development
Monitoring
and
Evaluation

2 (mainly)

1

0

6

1

1

1

0

7

5

2

3

1

7
2
3

2
1
2

0
1
0

2
1
2

3
1
1

4

0

0

0

2

The uneven policy development can be explained by numerous factors, in particular by
differences in attention paid by policy-makers and input received in development of various
components. The higher ratio of approved to recommended policies in the sphere of regulation
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and quality assurance can be explained by (1) the large input provided by SCDNTE to this field,
(2) the tradition established in early 90s and then supported by the MoH and the Government that
registration and import require a strong legislative basis, (3) the fact that these issues were very
technical and it became possible to provide a relatively broader coverage for them in the Law
“On medicines” while other more understandable components have caused more disagreements
between stakeholders and were extremely shortened in the law’s text, and (4) the fact that the
SCDMTE’s political power was greater than of many of their opponents. After its creation in
1992, SCDMTE became the Centre of Excellence that employed highly qualified and motivated
professionals who started to develop policies and rules in order to be able to carry out their
routine functions. Because at that time the country needed to have its own independent system of
registration as soon as possible it was developed and introduced very rapidly. High professional
competence of the staff, a motivation to provide patients with quality medicines, and technical
cooperation with WHO made it possible to introduce systems which were able to assure the
quality of registered and imported medicines. As an organization responsible for implementing
regulatory functions, SCDMTE became interested in having an approved legislative basis for its
activity and certain regulatory documents were developed and approved. Being rather technical
and based on the Law’s requirements these documents faced minimal opposition and were
accepted by decision-makers quite rapidly. It is also important that as a state joint-stock company
funded from registration fees, SCDMTE has been able to finance activities it is interested in,
including hiring staff it needs.
Other policy components, in particular affordability and rational use, have not become
priority issues although everyone understands that these are significant problems. A general
approach was that people in poor country (even now when Armenia became a low middle53

income country) cannot afford medicines. For a long time policy-makers have not thought that
although Government cannot provide access to medicines at the level that high-income countries
do, it can improve the situation by introducing some cost-effective strategies which are able to
save money and improve performance. Because the Ministry of Health is generally responsible
for health policy in the country and policy on medicines is an integral part of health policy, it
would be logical to suppose that the Department of Pharmaceutical Policy in MoH is responsible
for this issue. Unfortunately, this Department has not usually had the necessary human resources
to develop policy suggestions. The Department consists of only a few people and has been
focused on its routine functions mainly related to managing some medicines supply issues
(donations, centralized procurement, etc.).
Although no single organization is formally responsible for rational medicines use it has been
promoted by the SCDMTE for a long time. A lot of work was done by them separately and in
collaboration with experts from other health care organizations to develop Standard Treatment
Guidelines (about 40 were approved and published). In addition, two National Formularies were
developed and published and drug and therapeutic committees were established in many medical
organizations. These activities were implemented as initiatives not supported by any legislative
basis. SCDMTE cannot draft regulatory documents containing appropriate policies these
documents would not be supported by existing legislation.
Thus, it can be said that two important challengers in the pharmaceutical sector, affordability
of medicines and their rational use, have not received necessary attention and are poorly
addressed. Developing and implementing a comprehensive NMP would require that the main
challenges are carefully and equitably considered and addressed, appropriate strategies are
identified to achieve defined objectives and responsibilities are clearly stated.
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5. Pharmaceutical policy process in Armenia
There are different models of the policy process. One of them is the “stages model”. This
model (Figure 1) suggests that the policy process proceeds step by step starting from “Issue
emergence”, then it reaches agenda and so on. The results of evaluation provide feedback after
what it starts again. This model was criticized, in particular, because not every idea passes the
stage of “Agenda Setting” and, thus, some ideas do not reach further stages, or because
implementation and evaluation stages cannot be separated (Birkland, 2011). Nevertheless, this
model seems to be the most suitable for describing policy process, in particular, pharmaceutical
policy in Armenia. It is also the closest to approaches suggested by WHO for NMP process and
by Roberts & Reich (2011) for pharmaceutical reforms.
Figure 1. The Stages Model of the Policy Process
Issue
emergence

Agenda
setting

Alternativ
e selection

Enactme
nt

Implementation

Evaluation

Source: Birkland, 2011
Step 1- Issue emergence.
During this stage different public problems emerge in a society (Birkland, 2011). In Armenia
there are still many small and big problems in the pharmaceutical sector that emerged in 90s and
are well-known for many years. The specific difference in the pharmaceutical policy process in
Armenia is that in the majority cases the policy process starts not from issue emergence but from
the problem’s solution emergence, for example from submission of a draft of policy or
regulatory document developed by any reformer to MoH. Pharmaceutical policy ideas were
developed in Armenia by different initiators. In 1992, the first pharmaceutical policy ideas were
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initiated by individuals. After SCDMTE was established, policy ideas were made mainly by this
institution where the majority of reformers were employed. In 2000s, SCDMTE’s staff was
developing drafts of sub-legislative documents and then presented them to the Ministry of
Health. Few policy proposals were developed and presented to MoH by the NGO “Drug
Utilization Research Group”. Some proposals were initiated by MoH. Drafts of sub-legislative
documents (on Good manufacturing practice, labeling, a new system of registration) have been
developed based on the analogous documents of EU.
The most recent policy development that led to approval of a program to address certain
pharmaceutical policy problems in 2012 was initiated very differently. The problems related to
medicines were pointed out by the President and the policy development process started in the
MOH after direct instructions to improve the situation from the top policy officials - the
President and the Government (Dumanyan, 2012).
Step 2 – Agenda Setting
The great majority of ideas (proposals) reached the agenda (meaning that proposals gain
sufficient attention from state officials, at least at the MoH level). The majority of
recommendations/drafts have been considered and discussed at least for some time. For example,
a draft of the Essential Medicines List for Children submitted by DURG is currently actively
under consideration in the MoH and SCDNTE.
Step 3 – Alternative selection
Proposals are generally submitted as drafts of policy or regulatory documents, not as a policy
papers suggesting different options. Alternative selection has been mainly made between three
choices: to focus on adoption and implementation of policy/regulation (this includes its
approval), to start considerations, or do nothing. The second decision was quite popular. The
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interesting example is the List of EML. Until 2007 it was updated every 2 years and each new
version was issued as a Decree of the Minister of Health. The last version developed by
SCDMTE in 2009 and submitted to MOH has been under consideration so long that has become
obsolete. Currently a new version of EML has been developed by SCDMTE and will be
submitted to the MoH very soon.
Step 4 – Enactment
Only parts of policy proposals have been enacted. Some proposals have been discussed
effectively and soon became policies (for example, GMP requirements in 2010). Some drafts
were under consideration for a very long time and have not been a priority among other
competitive tasks for a particular official, or because the consensus has not been reached, or
because the administration has changed and a new one was not interested (for example, a Draft
of Decree of the Minister of Health “On approval of Rule and conditions of narcotic and
psychotropic substance use for medical purpose” appeared in the late 2000s, has not been passed
yet and, it seems, even is not actively discussing). Some drafts were considered for years and
have not been accepted due to technical reasons (regulation on labeling has not been approved by
the Ministry of Justice due to various reasons and, finally, because of discrepancy between its
title and provision in the Law “On medicines”).
Step 5 – Implementation
Approved documents that cover issues related to medicines evaluation, quality and safety
have been developed by SCDMTE. These policies are generally implemented very well as
drafted. However, even in the cases when SCDMTE does not agree with the decisions approved
by the authorities, the staffs strongly follow them. For example, some changes on import rules
initiated by local wholesalers and approved by the Government in 2011 have been not welcomed
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by the SCDMTE staff, however new rules are strictly implemented. However, some provisions
clearly stated in the law have been never implemented in the private sector. For example, all the
prescription-only medicines (excluding those containing narcotic and psychotropic substances)
are dispensed from pharmacies without prescription although it is not allowed by the Law “On
Medicines”. Another example is the policy to prescribe medicines from EML to out-patients
who receive medicines in retail pharmacy free of charge or with privileges; nevertheless, almost
half of prescribed medicines are out of EML (Melikyan, 2011).
Step 6 – Evaluation
In Armenia there is no the system of monitoring and evaluation of pharmaceutical policy
(Armenia Pharmaceutical, 2010). Individual pharmaceutical policies introduced by MoH are
usually not monitored or evaluated.
6. Effectiveness of the pharmaceutical policy process in Armenia
Effectiveness of the pharmaceutical policy process in Armenia can be assessed according to
process and outcome indicators developed and presented in the Background. The results of
assessing policy process for selected policies are presented in the Table 3. The following four
policies were chosen: those which have led to developing a draft of NMP in 2003 and a draft of
new Law “On Medicines”, as well as to approval of the Government Decree “Rules of Good
Manufacturing Practice” (2010) and the Decision of Government meeting “On approval of
program on solving problems in state control in the area of Health care, as well as in
pharmaceutical policy; and list of measures ensuring implementation of program” (2012). These
four policies were selected because of the following reasons: the first two documents are the
most important ones for the country (national overall pharmaceutical policy and national law on
medicines) however, although drafts were developed long ago, they are not approved yet; the
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second two policies were recently developed and approved during a short-lasting policy process
although they cover only certain issues in the pharmaceutical sector.
It is seen from the table that PPP in Armenia has some strengths and weakness (strengths are
those activities for which appropriate indicators in the table get positive respond). Examples of
strengths are the following: international experience is taken into account when developing a
draft; also, drafts are mainly widely circulated for consideration with stakeholders. At the same
time, an evaluation system is never used and this is an important weakness of policy processes in
the country.
Based on the data in the table it can be said that PPP in Armenia is not effective because
process often do not reach its outcomes – well developed and actively discussed drafts of policy
documents are not approved without any clear reason, plans for implementation of those that
were approved are conducted only partly and evaluation is never done.
Data in the table suggest that drafts of policy documents are approved only when there is
political will/commitment at the Government level or the National Assembly level. Such
political will/commitment can be provided/rejected due to various reasons. On my opinion, the
main general reasons of a lack of political will related to medicines issues in Armenia are the
following: common wrong assumption shared by officials and the public that in a country with
restricted budget access to medicines cannot be improved significantly, so there is no need to
make efforts; medicines are not considered to be a priority among other pressing Health care
problems. In two cases (examples) presented in the table 3 policy support was provided because
at the time of approval these problems were widely considered in media, policy-makers were
interested to demonstrate their readiness to implement social reforms and there were no strong
opposition for such new policy among powerful stakeholders. It can be assumed that among
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three necessary for policy window streams suggested by Kingdon (2003) – streams of problems,
policies and politics, politics is probably the most valuable in Armenia because problems exist
for a long time, solutions are suggested time to time (drafts of proposal), however due to lack of
favorable political sources policy proposals do not became active. At the same time, when there
are certain happenings in policy stream (for example, changes in the Ministry/Government or
elections are expected), the Government becomes very active, makes social issues priority and
provide political will/commitment at least for some time. The new Minister of Health initiated
operative research in the pharmaceutical field; in addition, the President has paid more attention
to health and pharmaceutical issues during his reelection campaign. All this has led to rapid
development and approval by the Government of a new program addressing some problems in
the pharmaceutical sector and also developing a new draft of a new Law “On Medicines” that is
currently considered by the National Assembly. Thus, opportunity window that existed in 2012
created conditions for some positive changes at the Government level (approval of program,
pushing a draft of law to the National Assembly). However, at present it is not clear whether the
National Assembly will demonstrate enough political will/commitment and whether a new draft
will be passed by the National Assembly, and even if so – when and with which deletions. The
reason is well known – difficulties in reaching consensus on some important issues because
stakeholders have conflicting interests in this field and some of them have support in the
Parliament; also, a draft suggests numerous changes and not all provisions seem to be evidently
useful or implementable. Due to political will at governmental and parliament level these
considerations can continue years and years.
Thus, it seems that the most important factor influencing effectiveness of the pharmaceutical
policy process in Armenia is political will/commitment. Without appropriate support any policy
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proposal, does not matter how well-developed it is, will remain just good intent. It is important to
identify and introduce strategies which could be able to improve political will/commitment
regarding to the pharmaceutical policy in the country. In Australia consumers were at the heart of
debate which have led to developing policy document (Walsh, 2011), however in Armenia there
is no patient organizations and it would be naïve to expect that they will be founded and became
strong in the near future; consumer organizations are relatively weak and have no enough power
to press the Government. Creation of powerful advocacy coalition that would include many
stakeholders which are sharing values and interests could be a more promising strategy. Such
Coalition could support patient’s interests, and be much more influential due to involving
professional organizations (which can always provide expertise), consumer and other NGOs
(including international NGOs), political activists, representatives of media and other interested
stakeholders.
Table 3. Process and outcome measures for the pharmaceutical policy process in Armenia
(four examples)
Process measures

NMP
(2003) Draft

New Law
“On
Medicines”
- Draft

“Rules of
GMP”
(2010)

Responsibilities for policy
formulation are defined.
Operational research is
implemented to provide
baseline data
International experience on
policy strategies is studied.
A policy paper on the issue
considered is written and
presented to policy-makers
(should include brief description
of the current situation,
evidence based policy options).

No

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Data were
available from
other sources
Unknown

Yes

No

Yes

No

Program on
solving
problems of
Pharmaceutic
al policy
(2012)
Yes
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Stakeholder analysis is
implemented.
Government or National
Assembly commitment is
ensured.
Draft of a final document is
presented (if it is a policy
document it should include
goals and strategies to achieve
these goals; if it is
legislation/regulation document,
it should include appropriate
provisions).
Draft is made publicly
available.
A national conference/meeting
is organized to present the final
draft (all stakeholders including
patient/consumer organizations
as well as media are invited).
Draft of Implementation plan is
presented.
Draft of evaluation system is
presented
Drafts are circulated for
consideration.
Funding is provided.

No

No

Yes

No

No

No

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Unknown

No

No

No

No

No

No

No

Yes

Yes

Yes

No

No

No

Yes

Yes

Partly

No

No

No

No

Draft of Implementation plan is
formally approved.

No

N/A

Draft of evaluation system is
formally approved
Outcome measures

No

N/A

Partly (for
regulation
by the State)
Yes
(strategic
plan)
No

Stage of Formulation:
document is formally approved.
Stage of Implementation and
Monitoring: All activities in the
Implementation plan are
implemented.
Stage of Implementation and
Monitoring: The final
evaluation is made and
distributed.

No

No

Yes

Yes

-

-

Partly

Partly

-

-

No

No

Yes (strategic
plan)
No
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7. Strengths and weaknesses of the pharmaceutical policy process in Armenia
This brief description of the pharmaceutical policy process in Armenia, the information
presented in the case study (see below) and the previous sections indicate that there are important
strengths and weaknesses in the Armenian pharmaceutical policy process.
Box 2.
Case study: Draft of a new Law “On Medicines”
Very soon after approval of the Law “On Medicines in 1998, it became evident that this first document did not cover
many necessary issues (for example, functions of a Drug Regulatory Authority, a system of ensuring affordability of
medicines) and, correspondingly, did not provide a reliable legislative basis for the Armenian pharmaceutical sector.
It was clear that the country needed a new law providing more detailed provisions related to medicines and
pharmaceutical services. A draft of a new law “On medicines” was formulated by the SCDMTE in 2003 and
submitted to MoH for consideration. Many corresponding regulatory documents which suggest policies for different
components of the Pharmaceutical sector have also been developed in order to be considered after approval of a
Draft.
After being reviewed at the MoH level a Draft was submitted for the Government consideration and then – to the
National Assembly (Armenian Parliament). It was widely discussed with involving numerous stakeholders:
pharmaceutical associations, local industry, academia and so on. Considerations in the National Assembly (NA)
have not been completed until its term of office for the acting was expired. In further years a draft was many times
considered at the different levels: MoH, Government, NA, however, has not been passed yet.
Another draft of new Law “On medicines” was developed by SCDMTE in 2012 after Government’s decision that a
new Law should be prepared. This new draft was submitted to MoH and became available for comments being
presented at the MoH official web site. Comments were collected until December 2012, then they were carefully
reviewed by SCDMTE and appropriate changes were made. Currently this draft is considered by the National
Assembly. Thus, it can be said that a draft of new law “On medicines” is at the policy agenda already 10 years.
This new draft covers the following aspects: regulation, principles of state policy, a state system of ensuring
medicines affordability, a system of medicines provision free and with privileges, price regulation, drug
development, clinical trials, registration, adverse drug reactions monitoring, manufacturing, packaging, labelling,
import and export, transportation, storage, distribution, information, advertisement, inspection. Numerous regulation
documents providing detailed interpretation of Law’s provisions will be introduced soon after approval on a new
law.
The most harmful effect caused by delay in approval of a new Law “On medicines” is impossibility to consider and
approve numerous regulatory documents required by it. Both old and new drafts include numerous provisions
requiring approval of regulation documents covering the most important policies in the pharmaceutical sector. The
majority of these requirements is not included in the existing Law and, correspondingly, sub-legislative documents
cannot be issued. Uncovered documents include such vital issues as the state system of ensuring affordability of
medicines and price regulation.

Strengths
1. There are some organizations in Armenia in addition to MoH which are interested and
capable to develop policy proposals including drafts of policy and legislative documents.
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These organizations are able to move issues to policy agenda. SCDMTE is a very strong
institution that has relatively good funding and human resources; it is able to develop
drafts of legislative/regulation documents especially those which would serve as a basis
for providing effectiveness, safety and quality of medicines.
2. Policy proposals are mainly well prepared and ready for considerations; the majority of
them take into account International experience, recommendations of WHO, local
conditions.
3. Many stakeholders are involved in a process of policy and regulation drafts consideration
and have a chance to defend their opinion.
4. Drafts of the main legislative documents are available at MoH’s official web site and any
written comments on drafts can be submitted to MoH.
Weaknesses
1.

Problems are rarely considered and/or addressed by state officials themselves; instead
these officials consider ready proposals which could be seen by them not as a priority.
An important exception is the situation in 2012 when certain problems were
recognized and certain promises (Sargsyan, 2013) and decisions (Decision, 2012) were
made. Other examples of initiatives which came from officials include those when the
MoH staff drafted a policy on creating cost-effective mechanism for reimbursement in
2005, formulated rules on transportation and storage of medicines in 2010 and made
couple other suggestions. These cases make a small but the most successful part of
policy developments, because the proposals were rapidly discussed (if discussed at all)
and approved. It seems that emerged interest to issue and support from decisionmakers plays the most important role in the Armenian pharmaceutical policy process.
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Problems may exist for a long time, be moved to policy arena, however, real steps to
solve them are made mainly when a political will is provided.
2.

Although policy consideration is an important and positive process, it is clear that
policy-makers in Armenia have difficulties reaching consensus. Stakeholders in
Armenia, like everywhere, have competing interests related to medicines, and this
causes delay in approval of extremely important documents like it happened with a
draft of Law “On medicines”.

3.

Although many stakeholders are involved in policy deliberations, they have very
different political power and, correspondingly, are able to defend their interest with
very different success. For example, wholesalers were able to convince the
Government to make some changes in rules on import although it may compromise the
quality assurance system. The weakest stakeholder in the country is
patients/consumers. There are no patient organizations in Armenia due to certain
reasons: absence of such tradition; a small population and, appropriately, relatively
small number of patients with the same disease; many patients are poor, fighting for
survival and do not have time and knowledge to create or be involved in voluntary
activities, a lack of trust in effectiveness of a public activity. Consumers’ organizations
are poorly educated and not active in the area of the pharmaceutical policy. The
patients’ interests are presented by state officials but these are among other competing
interests. Some professional associations and representatives of Academy try to defend
patient’s interest, however, these stakeholders have a little political power and,
correspondingly, often ignored. Those organizations which are most interested in
promoting affordability of medicines, their safety and rational use are often not
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involved in policy discussions and, also, do not have any funding to support their
activity in this area.

Part II. Pharmaceutical policy process in Newly Independent States
There are limited data on the pharmaceutical policy process in NIS. Unfortunately, it was
impossible to find studies examining and analysing the direct outcomes of a NMP document
approval. Although NMP are approved in many NIS, they are rarely monitored and the results
are not published. In addition, it probably would be very complicated task to assess the role of
having approved document because numerous other factors also influence the final results in
very rapidly changing political, social, economic environment in these countries during the last
20 years.
The only publication available that presents the results of study intended to assess a role of
NMP implementation in NIS, is one that covers four countries from the Middle Asia region –
Kazakhstan, Kyrgyzstan, Tajikistan and Uzbekistan (Nurgojin, 2004). Based on the data
collected mainly through interviewing key persons in mentioned countries authors have
concluded that certain elements of NMP recommended by WHO were observed in all the
countries studied; in Kyrgyzstan the concept of NMP was introduced more widely and the level
of availability of medicines was higher.
Thus, due to lack of data on evaluation of NMP outcomes in NIS, only important elements of
the pharmaceutical policy process itself have been examined and are presented here: existence of
formally approved NMP document and implementation plan, its monitoring and evaluation,
involvement of stakeholders. Some data are summarized in Table 4.
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Table 4. National Medicines Policy documents in Newly Independent States
Country

Formally approved
NMP document

Data of
approval

Available at:

Armenia

Azerbaijan

No
(Azerbaijan
Pharmaceutical, 2011)

Belarus

Resolution of Council of
Ministers № 1192 “About
concept of medicines
supply of Republic of
Belarus” (Reutskaya,
2008)
As a part of the National
Health Policy
(Chanturidze, 2009)
Government Resolution
№ 584 – “Concept of a
medicines policy of the
Republic of Kazakhstan”

Georgia

Kazakhstan

August 13th,
2001
(Reutskaya,
2008)

1999
(Chanturidze,
2009)
May 29th, 2002

The last Draft
of NMP

Implementation
plan, year

NMP as a part
of NHP (2006)
(Armenia
Pharmaceutical,
2010)

No
(Armenia
Pharmaceutical,
2010)

System of
monitoring
and evaluation
No
(Armenia
Pharmaceutical,
2010)

No
(Azerbaijan
Pharmaceutical,
2011)

Not regularly
(Azerbaijan
Pharmaceutical,
2011)

http://spravkajurist.com/base/
partbz/tx_wsxeoy.ht
m

Concept of
National
medicines
policy of
Republic of
Kazakhstan for
2012-2016
(2011)
www.nv.kz/file
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Kyrgyzstan

Moldova

1. Resolution of the
Government №794 “On
State medicines policy of
KR”
2. Resolution of the
Government №704, NMP
for 2002 – 2005
3.KR Government
Resolution N 11 "About
National medicines policy
of Kyrgyz Republic for
2007 - 2010"
(Kyrgyzstan
Pharmaceutical, 2011)
1.“National policy in the
field of medicines”
approved by Board of
Ministry of Health (Safta,
in press)
2. Decision of the
Parliament of the
Republic of Moldova
nr.1352 approving the
State Policy in the Field of
Medicaments (Cuza)

1. December
4th, 1998
2. October15th,
2002
3. January 12th,
2007

1.1997
2. October 3rd,
2002

3.
http://pharm.kg/r
u/policy/

s/lekarstva..doc
http://www.mz.
gov.kz/page/pro
ekty-dlyaobsuzhdeniya
2nd Draft.
NMP2014-2020
(May 27th,2013)
http://metakg.o
rg/upload/news/
NDP_270513.p
df

1. 1998
(Kurmanov,
2006)
2. 15th October,
2002
3.KR
Government
Resolution №
11 of January
12th, 2007
(Kyrgyzstan
Pharmaceutical,
2011)

1.2001
2.NPM
implementation
report, 2010
(Kyrgyzstan
Pharmaceutical,
2011)

1. 2002 (after
Yes
NMP approval in (Republic of
2002)*
Moldova
Pharmaceutical,
2. 2007
2011)
(Republic of
Moldova
Pharmaceutical,
2011)
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Russia

Decree of Minister of
Health N 66 “Strategy of
medicines supply for the
period until 2025”

February 13th,
2013

www.consultant
.ru/document/co
ns_doc_LAW_1
42725/

Tajikistan

Decree No. 368 of the
Ministry of Health on the
National Drug Policy
(Khodjamurodov, 2010)

August 28th,
2003

http://dictaj.uco
z.ru/load/naciona
lnaja_lekarstven
naja_politika_rt/
1-1-0-2

Resolution of MoH Board
“National medicines
policy of the Republic of
Uzbekistan» (Nurgozhin
2001)

May 30th, 1999
(Nurgozhin,
2001,
Uzbekistan
Pharmaceutical,
2011)

http://zakonuz.u
zshar.com/?docu
ment=5947

Turkmenistan
Ukraine
Uzbekistan

Yes
(Uzbekistan
Pharmaceutical,
2011)

Yes
(Uzbekistan
Pharmaceutical,
2011)

Note: * (in the table and further in the text) - the data are provided by DURG PO (Armenia); these data were submitted by leading experts from six
countries: Armenia, Belarus, Georgia, Kirghiz, Moldova and Ukraine to the DURG in 2003 during implementation of a special project.
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1. Existence of NMP document
The data available indicates that NMP document has been formally approved in the majority
of NIS (eight of twelve). NMP is mainly available as a document, in one case (Georgia) – a part
of a document. In five countries (Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Uzbekistan)
officially authorized document has the name including the term “medicines policy”, in two
countries (Belarus and Russia) – “concept of medicines supply”. In one country (Georgia) –
NMP is a part of the approved “National health policy” document. In six countries the current
NMP has been authorized at a high level as a formal document: in four - by the Resolution of the
Government/Council of Ministers, in one (Moldova) – by the Parliament and in one (Georgia) –
by the Ukase of the President*. In three countries (Russia, Tajikistan, Uzbekistan) it has been
approved by the Ministry of Health.
In many of the countries documents having a various status and name but in fact being a
written description of comprehensive NMP, have been approved soon after independence.
According to WHO data, nine countries have approved NMP still in the first five years
(Saoutenkova, 2003). Recently the significant changes in situations alongside with understanding
of that many problems have not been solved yet, have led to renewal of the interest to a
medicines policy. Russia approved its document in February this year, Kazakhstan and
Kyrgyzstan have developed drafts of new NMP in 2011 and 2013, correspondingly, and these
documents are currently under consideration. In May 2013 Kyrgyzstan developed the Second
draft that is intended for 2014-2020 (Kyrgyzstan 2nd Draft, 2013).
Analysis shows that some countries formulate and approve a new NMP when they consider
their existing document to be obsolete. Thus, the last authorized NMP document in Kyrgyzstan is
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already the third one and Kyrgyzstan formulated a draft of the forth document for the period of
2014-2020; in Kazakhstan and Moldova the last approved document is the second one.
The interesting lesson from countries experience is that in the several countries (Kazakhstan,
Kyrgyzstan, Moldova) where NMP has been initially approved at a level of Ministry of Health or
as administrative document during advisory meetings, the further version of NMP has been
passed as an official document (Kazakhstan, Kyrgyzstan) or at higher level (in Moldova the last
document was approved by the Parliament). Existence of a document with the official status
allows a higher level of performance and authorization by the Government/Parliament of the
country allows the involvement of all the necessary sectors simultaneously. According the
opinion of key informant from Russia, the document was approved by the Health Ministry but
not by the Government (as was originally expected), so in fact it is not a National Strategy, but
rather an internal ministerial paper.
2. Formulating NMP
Formulating NMP in NIS took place in the certain degree according to the recommendations
of the WHO. This is the result of the activity carried out by WHO, especially by the Regional
Office for Europe from the beginning of 90s. Organization of a process of formulating a NMP
document was carried out mainly by the Ministry of Health/corresponding departments or
Medicines Regulatory Authorities. In many cases drafts of documents have also been prepared
by the MoH/corresponding departments, for example in Belarus, Georgia, and Kyrgyzstan. In
Moldova, for example, a draft has been prepared jointly by the National Institute of Pharmacy,
the Pharmaceutical faculty of the State Medical Pharmaceutical University named after Nikolay
Testemitsanu and the MoH, Republic Moldova*. Document in Russia was prepared by MoH
(key informant from Russia).
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There is a lack of the information on whether development of documents has been based on
an analysis of the situation. In the Kirghiz Republic, for example, formulating a draft of the
second NMP document was based on assessment what was carried out with use of a set of the
WHO indicators. According the opinion of key informant from Russia, the document adopted by
MoH in February was not based on sound situation analysis and was not comprehensive, in
particular, practically does not include plans for strengthening of the medicines regulatory
system - the only indication was “international harmonization” .
Involvement of the interested parties, in particular, representatives of a legislative bodies,
various ministries, departments, universities and so forth in discussions on a draft of a NMP
document is noted in nearly all the countries. The example of Kazakhstan is interesting. As it
was already mentioned, at the beginning the document “State policy in the sphere of medicines
circulation” was approved by the Pharmaceutical section at the Conference in 2001; then in 2002
this document was published in the professional newspaper and journal in order to provide a
wide involvement of interested parties in discussions. The suggestions submitted, for example,
those suggested by the head of a professional nongovernmental organization, were published in
the same newspaper (Berkman, 2002). Nevertheless, it is obvious, that almost everywhere the
number of participants involved in development/discussion of a NMP is limited. Examples of
cases of involving consumer or patient organizations, or other non-professional NGOs in
pharmaceutical policy process have not been available in publications. Involvement of the public
professional organizations in a process of NMP development is also limited. On the other hand,
the professional community in some countries come with very serious initiatives on the issues
connected to a medicines policy. An interesting example is approval of the document “Concept
of developing the pharmaceutical sector” at the VI National congress of pharmacists in Ukraine
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in 2005 (The concept, 2005). In Russia necessity of developing a NMP document and also
possible approaches to its formulating have been actively discussed and moved ahead by leading
experts (Meshkovsky 2000, Beregovikh 2005), presented at various conferences and sessions of
public organizations, round tables, and also in professional publication. The Chamber of
Commerce and Industry of Russian Federation of the Russian Federation has played an active
role (RF CCI, 2004).
Today, in the NIS there is a significant number of public professional organizations
involving many qualified and interested professionals. Although they basically have no
significant experience participating in the pharmaceutical policy process, this huge potential of
professionals can and should be involved in formulating and discussing drafts of a NMP. It is
difficult to overestimate the contribution the army of professionals can bring to development of
the pharmaceutical sector of their countries.
Countries have not organized active campaigns on launching NMP but in some of them the
information about approval of the document was published or presented in the Internet,
especially those approved in the last 10 years. For example, a detailed information about signing
the Resolution of the Governments of Kyrgyzstan on КР NMP for 2007-2010 was submitted on
16th January, 2007 on the State Internet portal site; the article contains certain details of the
document including the main observations and tasks. There is an access in the Internet to the full
text in Russian of NMP documents of Belarus, Kyrgyzstan, Russia, and Tajikistan.
3. Implementing and monitoring NMP
Although NMP documents are available in the majority of the countries, implementation
plans based on the policy are developed only in some of them, including Belarus, Kyrgyzstan,
Moldova and Uzbekistan. This has not significantly changed compared with the 1990’s when it
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was also noted that most national drug policies lacked an operational implementation plan or
adequate monitoring mechanisms (WHO, 1998). According to the WHO approach based on
various countries’ experience, without the plan of implementation medicines policy process
remains a dead document (WHO, 2001). Accordingly, it is important for NIS to not only pay
attention to developing the NMP, but also to continue work to develop an appropriate
implementation plan to concretize actions, responsibilities, budget, and other terms.
It is also important to remember that implementation of NMP is a common task in which
various ministries, the private sector and many other stakeholders are involved. Accordingly,
coordination of actions, involvement of all interested parties to both formulating plans and their
implementation and monitoring is necessary.
The Ministry of Health in most countries cooperates with other state bodies and provides
public relations. For example, in Kazakhstan, after setting up the Committee on pharmacy,
pharmaceutical and medical industry in its semi-annual report to the MoH Board a wide activity
carried out in this area was specified. Agreements related to issues of pharmaceutical products
between the MoH and other ministries and sectors have been prepared visits to regions and
meetings with businessmen, nongovernmental organizations have been carried out. Problems
were discussed in mass-media, including TV, on constant basis (Pak, 2002). However, to obtain
the best possible outcome from PPP, it is necessary that implementation activities be carried out
by all participants according to the discussed and approved plans based on a NMP.
For coordinating activity and also PPP monitoring a special division in the MOH could be
expedient. In few NIS there are divisions/units responsible for medicines policy issues. In
Uzbekistan, for example, there is “Centre of a policy of medicines and devices” of the MoH, the
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main purpose of which activity is introduction and implementation of a strategy of the Ministry
of Health in the field of the national policy on medicines and devices.
In nearly all NIS, studying and assessing the situation in the pharmaceutical sector is carried
out to some extent and the results are published in scientific journals, other professional
publications, and also in mass-media, on official sites of the Ministries of Health and Medicines
Regulatory authorities of the countries, etc. Certain information on implemented reforms and the
strategy are also presented. Nevertheless, the qualitative and quantitative data usually are not
related to NMP or a plan of implementation’s contents. Such data indicate some achievements
and problems in the pharmaceutical sector, but do not provide the opportunity to carry out
monitoring and evaluation, and, accordingly, to draw a conclusion about progress in achieving
the NMP goals and objectives. According to the WHO, although quality evaluation is useful, it
cannot replace the need for quantitative measurement of the factual data. Use of the fixed
package of indicators is necessary for ensuring that repeated and compared monitoring can be
carried out (WHO, 2004).
4. Factors influencing NMP
Political will. In a number of countries (Belarus, Kazakhstan, Kyrgyzstan, Moldova)
NMP documents have been developed by corresponding departments of the MoH or Medicines
Regulatory Authority with participation of the MoH, and then have been authorized at a level of
Resolution of Government/Council of Ministers and even the Parliament (Moldova) that clearly
demonstrates commitment and suggests the level of political will of the country’s authorities to
improve the situation in the pharmaceutical sector. Some countries specify the political will of
authorities. For example, in Uzbekistan it is considered, that a dynamic development of the
pharmaceutical sector in many respects was the result of explicit decisions by authorities of the
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Republic, and in particular, the State joint-stock concern "Uzpharmsanoat” to support the
development of this sector. Also, a number of the governmental decisions supported the
establishment of a local pharmaceutical industry. Nevertheless, there is a lack of political will in
many countries. In Russia, where the concept of NMP has been actively promoted by a number
of leading professionals and organizations, an appropriate document appeared only this year. In
the majority of countries the political will of the government was enough for documents
approval; implementation plans have not been developed and/or systems of monitoring and
evaluation have not been introduced, however.
Support and the technical assistance from WHO. The majority of the countries specify
support and the technical assistance of the World Health Organization. Administration of the
pharmaceutical service in the MoH of the Kirghiz Republic notes that the development of a NMP
started in 1994 at the advisory meeting with the WHO experts participation, and then, in 2001
the evaluation of NMP introduction was carried out with the methodological support of WHO
and based on the results of NMP implementation for the period of 1994-2000 a new draft was
developed (Kurmanov, 2006). Support from the WHO Regional Office for Europe on issues
related to formulating and implementing NMP is noted also by representatives of Kazakhstan
(Kulakhmetova, I. 2000) and Tajikistan (Isupov, in press). Publication in Russian and English of
the strategic document “The patient in Focus. A Strategy for Pharmaceutical Sector Reform in
Newly Independent States”, prepared by the WHO Regional Office for Europe and the WHO
Action Programme on Essential Drugs has provided an important methodological assistance.
“The publication describes pharmaceutical sector reform in the newly independent states and sets
out strategies for its further development. This global strategy will function as a guideline for
further reform at country level” (WHO, 1998). Numerous consultations, seminars and other
76

support intended to increase a level of knowledge of countries’ experts in this sphere have been
also carried out. A fortnight training seminar organized in 2002 in Tashkent should be noted
along with other presentations in the area of NMP, including the special lecture "Process of a
medicines policy”.
Existence of resources. In many NIS there are insufficient resources for NMP
implementation. In the opinion of the expert from Moldova, for example, the absence of a state
financing intended for introducing NMP is the main weak link in their NMP*. According to the
data available* in many countries special funding for introduction of NMP has not been planned.
It is important to note, that in Kyrgyzstan where the pharmaceutical policy process is organized
better than in many other counties of the region (e.g. an updating of the document on a regular
basis - each 4-5 years, regular approval of appropriate implementation plans, monitoring
according to indicators), a special financing on implementing a policy in the sphere health care
has been allocated (the credit from the World bank)*. Absence of a specially allocated budget
seems to be an important barrier influencing an active implementation of NMP in other NIS.
Human resources. Numerous highly skilled professionals are employed in the NIS by
different public and private organizations. In many cases individual experts and institutions
initiate and support issues related to NMP. In the early 90’s professionals from the countries of
the former USSR heard the term “NMP” for the first time. Due to support from the WHO the
concept of NMP has quickly spread in this region; however, initiatives of the countries were also
very important. Ukraine and Kazakhstan, for example, have published the important materials
including translation into Russian of the last WHO guidelines «How to develop and implement a
national drug policy in their main professional editions. However, there are certain factors
connected to human resources which will influence PPP: insufficient number and, accordingly,
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excessive overload of officials by routine activity; need to solve at once many unresolved
problems in the pharmaceutical sector, including improving legislation; a low motivation due to
an inadequate payment; a lack of knowledge and experience in sphere NMP and a lack of access
to the appropriate information; a lack of researchers and, appropriately, necessary data.
Therefore, increase of a level of knowledge in the area of NMP and the pharmaceutical sector
management remains an actual task. Increase of a level of motivation and responsibility and
promotion of ethical standards among the experts involved in the sphere of management and
regulation in the pharmaceutical sector also seems essential.
5.

Lessons learned from PPP in NIS
Some lessons can be learned from the experience of NIS on developing and implementing

pharmaceutical policy; these lessons can be useful for Armenian policy analysts and policymakers.
1. Having formally approved document of NMP can be considered to be useful for
improving the situation in the pharmaceutical sector (eight of twelve countries have
formally approved document, three of them have approved also the second one or
developed a draft for approval; in two of four countries where there is no formal
document, NMP document has been approved by professional bodies and countries have
been trying to have a formal document; all this suggests that NIS found out having a
formally approved document to be useful).
2. It is preferable to approve a NMP document at the governmental or higher level (in five
of eight countries formal documents including the second/third ones were approved by
Government, Parliament or President; new drafts in these countries are also intended to
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be approved at the same level; this suggests that countries found out this high level to be
appropriate).
3. It is important to make a draft of NMP document publicly available and provide
conditions for wide consideration with involving different stakeholders; it is also
important not only collect suggestions, but also to take them into account (drafts of NMP
documents considered and approved during the last decade were available through
professional or other media; opportunity to submit comments was provided; it is unclear
whether suggestions were taken into account, and there is opinion (informant from
Russia) that comments were accommodated in an inconsistent manner).
4. Due to absence of system of monitoring and evaluation countries are not able to evaluate
their progress in the pharmaceutical sector even if they fix changes of some indicators
(Kyrgyzstan is the only country among NIS that implements monitoring of NMP).
5. Patients’ including consumers’ organizations are currently not able to make a difference
in the pharmaceutical policy process in NIS, so it is important to identify an
organizational framework that would be able to influence PPP in order to improve it and
provide appropriate outcomes of the process and pharmaceutical policy.

Part III. Discussion and recommendations on pharmaceutical policy process
in Armenia
Discussion
The results of analysis of process and outcome indicators as well as other data presented
in the Part I have shown that the pharmaceutical policy process in Armenia is not effective
because it does not provide appropriate outcomes – the necessary law and regulation documents,
policy documents and actions; correspondingly, not-existing policies cannot be implemented;
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even those policies which are approved are implemented only partly and not monitored. The
main reason can be lack of political will because other elements important for successful policy
implementation and known constraints do not currently cause much concern as possible barriers.
MSH (2011) suggests the following main constrains for successful NMP: lack of political will,
lack of resources, opposition and corruption. Lack of resources that is always an important factor
in middle-income countries is not an important barrier for formulating and implementing the
majority of not-existing in Armenia but cost-effective policies in particular those addressing
rational medicines use. It is well-known that there are many highly-qualified professionals in the
country that could be involved in policy formulating and implementing, so lack of human
resources is also cannot be considered as an important constrain. Opposition to pharmaceutical
policy issues in Armenia is not very strong because different organizations have various interests
even if they represent a single stakeholder, so they rarely join to defend their common interests;
however, opposition is able to create barriers now because the Government and the National
Assembly do not provide necessary political will and commitment (there are numerous strategies
allowing to diminish or eliminate efforts of opposition which are currently not used). Corruption
is considered to be very active in Armenia, and certainly can be a constrain for approval of
certain policies and policy enforcement, however, if the Government would demonstrate
appropriate political will through introducing transparency and accountability mechanisms and
through evaluating policy implementation, corruption can be easily eliminated in the majority of
areas dealing with medicines. For example, some physicians ignore the rule requiring to
prescribe medicines from the Essential medicines list to those patients who receive medicines
free of charge, due to corruption. MoH could easily require reports from appropriate medical
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establishments and analyze the situation. Being accountable, physicians would be afraid to break
the rule and will stop to ignore it.
Lack of political will and commitment is frequently met issue everywhere and rarely is
provided sufficiently or for a long time. Phanouvong with co-authors (2002) identified that in
four countries they studied the ministers of health and the cabinet played a crucial role in
medicines policy initiation, however, once the policy was launched in Laos, Thailand and the
Philippines a decrease in political will and commitment had occurred, and this had slowed the
progress of NMP. In Australia, where governments demonstrated commitment to continued
funding of NMP, the policy was implemented more effectively.
It is not easy task to improve political will in the country. It is considered that in 90s the
development of the Australian NMP was the result of strong consumer (civil society) advocacy
and lobbying (Robertson, 2012). Thus, we can assume that continuing government commitment
was caused and supported by efforts of consumer (civil society) organizations and possibly this
experience can be useful for other countries. Unfortunately, consumer activism in other countries
(such as India, Thailand and China) was less successful due to a lack of financial support for
consumer groups and poor access to policy makers. Summarizing the results of the Asia Pacific
Conference on National Medicines Policies Robertson and co-authors (2012) concluded that
“Consumer groups have an important role in ensuring policies are implemented.” (p.190),
however engaging civil society to pressure governments to deliver appropriate medicines
policies remains a key challenge.
Experience of Armenia and other NIS suggest that in this region patients/consumers
groups are not sufficiently strong (for example, in Ukraine NMP document is not approved
despite advocacy provided by consumer organizations), however there are many different other
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NMP advocates such as academy, professional NGOs and associations. It seems that only joint
efforts could be able to pressure the Governments sufficiently to provide appropriate political
will and commitment on issues related to medicines. Advocacy coalitions involving different
stakeholders having same interests and similar values at least on some important issues could
provide enough pressure through evidence-based advocacy. Involved professional organizations
could provide data and analysis of situation, consumer/patients organization could provide the
results of case studies, media could be responsible for competent distribution of information,
some partners could provide necessary funding to ensure financial sustainability of the coalition.
Value of joint efforts was recently noted also at the Workshop “The role of NGOs in the
development and implementation of National Medicines Policy” that was held in December 2012
in Latvia (Workshop, 2012). Based on the results of discussion they arrived to various ideas
including that “Those non-governmental organizations which protect the interests of patients
should work together on problems where their opinions and needs are similar or identical, which
would increase their chances of being heard and empower them (especially when it comes to
organizations of patients).” MSH also supports such approach in its latest publication “Mobilizing alliances and coalitions and creating constituents inside and outside the government
are necessary to mobilize political will over the process” (MSH, 2011, p.4.5).
Based on the above-described approach I developed a pharmaceutical policy
process framework involving advocacy coalition (Figure 2). Although this suggested framework
has some similarities in main idea with the well-known Sabatier’s Advocacy Coalition
Framework (ACF) – an important model of the policy process which is based on the idea that
different interest groups can be organized in policy communities (Birkland, 2011), it is quite
different in interpretation. In the ACF 2 or 4 advocacy coalitions can form a particular policy
82

domain joining around shared set of core values and beliefs. The framework suggested by me is
developed particularly for PPP; it, correspondingly, includes coalition and those stakeholders
which are typical for the pharmaceutical sector. Policy making in suggested framework is not a
straight process like it is in ACF, but is a cycle because, the results of monitoring can reveal a
new problem or because one policy cycle is not always able to solve problem completely - so
policy cycle starts again. In the ACF policy process is influenced by two big groups of
parameters – “relatively stable” and “external (system) events”. In the framework suggested the
policy process is influenced by a coalition itself, other stakeholders in the sector, as well as more
broadly by policy environment (policy environment: “The structural, social, economic, political,
and other factors that influence and influenced by policy making”. Birkland, 2011, p.27). Policy
process outcomes (laws, regulations, policies, etc.) are influenced by and influence the coalition,
other stakeholders through PPP; and links between coalition and these outcomes are more
numerous and more strong than between outcomes and separate stakeholders. These additional
comprehensive links reflect additional opportunities of coalition to affect PPP and achieve policy
process outcomes.
Because a lack of political will is one of the most important constraints, but not a single
reason of PPP ineffectiveness in Armenia, certain recommendations for the policy process
improvement were developed and presented below.
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Figure 2. Framework of pharmaceutical policy process involving advocacy coalition
Policy
environment
Coalition

Problem

Monitoring

Policy process
outcomes:
laws, regulation,
policies, programs,
actions

Policy
formulation

Implementation
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Recommendations for different stakeholders
For the Government
1. To create a Multi-sectoral Commission responsible for pharmaceutical policy issues; to
ensure that the Commission consists of representatives of different stakeholders including
organizations representing patients’ rights; to ensure an access of media to meetings; to
ensure transparency of the commission’s activity.
2. To create and introduce mechanisms for enforcement of existing legislation in the
pharmaceutical sector
For the Ministry of Health
3. To implement comprehensive assessment of the pharmaceutical sector in order to get
reliable data necessary for (1) defining the main problems and their causes; (2)
developing evidence-based policy; (3) providing baseline data for a further policy
evaluation.
4. To create a working group consisting of leading national experts and representatives of
different stakeholders to develop a draft of a National Medicines Policy document that
will include: goals (long-term and medium-term), tasks, strategies to achieve goals (for
all selected components), sources of funding and timeline, a program of evaluation
including indicators for monitoring outcomes; to select the following components:
legislation, regulation, financing, pricing and reimbursement, supply, distribution,
pharmaceutical care, rational use, antibiotics, controlled medicines, waste, research,
human resources.
5. To develop a draft of the five-year Implementation plan together with NMP (not after
policy approval) and present it together with a policy document draft in order to provide a
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clearer picture of further actions and expected results; to include in the plan the following
information: activities, responsibilities, input, outcomes, timeline.
6. To consider drafts with all the interested stakeholders during initially decided period of
time (possibly 6 months), make changes based on presented comments and approve it as
a Government Resolution.
7. To create in MoH a special unit responsible for monitoring and evaluation of NMP; to
create a Public Commission (involving representatives of patients’, consumers’ and other
non-governmental organizations) to be involved in considerations of the results of policy
monitoring and evaluation; to provide transparency of unit’s activity and results received.
8. To monitor PPP according to indicators suggested and to provide the results to abovementioned Public Commission for consideration and revision.
9. To calculate, identify and ensure funding needed for policy implementation.
For Public (Non-Governmental) organizations - both professional associations and
representing patients’ interests
10. To participate actively in pharmaceutical policy formulation and consideration.
11. To be informed about the results of monitoring and evaluation and possible changes in
policy.
12. To create a strong advocacy coalition involving professional associations and consumer’s
rights organizations, media and so forth, that would be able to defend interests of
patients.
For International Non-Governmental) organizations
13. To provide some funding to ensure active participation of NGOs in policy process and
their independence.
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